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Abstract
Galectins are a family of β-galactoside binding proteins with roles in cellular differentiation,
apoptosis, and cancer progression. To better understand this important class of proteins, HL60 acute myeloid leukemia cells were used as a model for comparative study of the effects of
recombinant galectins, galectin inhibitors, and all-trans retinoic acid (ATRA) on granulocytic
differentiation. Targeted inhibition of galectin-1 or -3 induced characteristics of neutrophilic
differentiation including segmentation of nuclei, upregulation of neutrophil cytosolic factor 1
gene expression, and a global decrease in protein glycosylation with O-linked Nacetylglucosamine. Recombinant galectin-8 or -9 also induced granulocytic differentiation
that was not observed with recombinant galectin-1 or -3. However, the galectin induced
differentiation was moderate relative to the strong stimulatory effects observed with ATRA.
In silico analysis of acute myeloid leukemia data from the Cancer Genome Atlas revealed
changes in galectin gene expression profiles related to the various molecular subtypes of acute
myeloid leukemia. A ratio of galectin-12/galectin-9 gene expression was identified as a
potential diagnostic marker of leukemia subtypes. Correlation analysis between galectin gene
pairs revealed changes to the glycobiological landscape and relation to granulocytic
differentiation markers in leukemia cells. Among galectin genes, only the increased galectin1 gene expression was indicative of patient poor prognosis in all acute myeloid leukemia
cohorts. These results indicate that while galectins share similar structures, they elicit different
responses and display different gene expression patterns in relation to granulocytic
differentiation in acute myeloid leukemia. Furthermore, these findings suggest the possible
utility of galectins as targets for differential therapeutics.

Keywords
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Summary for Lay Audience
Galectins are a group of sugar binding proteins involved with the immune system and cancer.
Acute myeloid leukemia (AML) is a fast-acting cancer of the blood and bone marrow. Patients
with AML have weaker immune systems and lower immune cell counts because of a larger
number of cancer cells. To date, the treatments for AML include chemotherapy and many drugs
including all-trans retinoic acid (ATRA). AML poses issues in treatment and diagnosis due to
the wide range of genetic changes that occur within the cancer cells. In this study, different
galectins in HL-60 cells (an AML cancer cell line) were used to see how these proteins
influence the cell development of the immune system for possible new targets in AML
therapies.

In HL-60 cells, the inhibition of galectin-1 or galectin-3 as well as the

supplementary addition of galectin-8 or galectin-9 resulted in an increase in developed immune
cells. However, all galectin responses were weaker when compared to ATRA treated cells.
Galectins were also investigated to find new diagnostic and prognostic markers of AML.
When comparing galectins between healthy and cancer cells, galectin-9 and galectin-12
showed changes specific to cancer cells, serving as a new diagnostic marker. Additionally,
increased expression of galectins-1, -4 and -10 all serve as new prognostic markers in AML.
Overall, my findings revealed that galectins are related to the development of the immune
system and serve as new diagnostic and prognostic markers. This suggests that galectins might
prove useful as potential new targets for AML therapies.
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Chapter 1

1

Introduction

1.1 Acute Myeloid Leukemia (AML)
There are four different leukemias impacting immune cells including acute/chronic
myeloid and lymphocytic (AML, CML, ALL, CLL) leukemia. Acute myeloid leukemia
(AML) is a fast-progressing blood cancer that affects myeloid origin cells including
leukocytes, erythrocytes and megakaryoblasts (Luczak et al., 2012; De Kouchkovsky &
Abdul-Hay 2016).

The result of AML is an increased amount of terminally

undifferentiated and immature cancerous cells in the bone marrow, preventing healthy
blood cell production, differentiation, and maturation (De Kouchkovsky & Abdul-Hay,
2016; Lohse et al., 2018). Side effects that can be observed in AML patients include
improper immune function, anemia, and hemorrhaging. The incidence of AML has
increased over the past decade, especially among older adults who demonstrate poor
prognosis (Lohse et al., 2018; Short et al., 2018). Currently, AML subtype identification
follows the French-American-British (FAB) classification system, where the eight
different subtypes of AML are categorized as M0 through M7. Patient classification is
based on cell nuclearmorphology, cytochemical testing, and genetic abnormalities (Dalton
et al., 1988; Hassan et al., 1993; De Kouchkovsky & Abdul-Hay, 2016; Walter et al., 2013;
Asthana et al., 2018; Lohse et al., 2018; Short et al., 2018). Current treatments for AML
include cytotoxic chemotherapy and various other drugs, including all-trans retinoic acid
(ATRA). However, AML has high genetic heterogeneity due to distinct cytogenetic
abnormalities, somatic mutations, and changes in the epigenome, resulting in difficult
subtype classification and difficult treatment (Walter et al., 2013; Lohse et al., 2018).
Induced differentiation therapies are one of many new treatments being investigated for
AML, with galectins representing an intriguing target for these therapies.

1.1.1

AML FAB subtype classification

AML FAB subtype classification indicates which cells during myeloid cell maturation are
cancerous, resulting in the accumulation and secretion of these cells from the bone marrow
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into the blood (Figure 1). Each subtype represents a different stage of maturation when
looking at myeloid cell differentiation (Lohse et al., 2018). M6 and M7 are rarer forms of
AML and are not associated with leukocyte differentiation (Hassan et al., 1993). There are
various genetic mutations that occur resulting in inhibited leukocyte differentiation,
including mutations in the RUNX1, C/EBPα, PU.1, among other transcription factors (De
Kouchkovsky & Abdul-Hay, 2016; Lohse et al., 2018). When looking at leukocyte
maturation, subtypes closer to the HSCs are considered more immature and contain more
stem-like properties. AML FAB subtypes include M0 (undifferentiated acute myeloblastic
leukemia), M1 (acute myeloblastic leukemia, <10% maturation), M2 (acute myeloblastic
leukemia, >10% maturation), M3 (acute promyelocytic leukemia, APL), M4 (acute
myelomonocytic leukemia), M5 (acute monocytic leukemia), M6 (acute erythroid
leukemia), and M7 (acute megakaryoblastic leukemia) (Hassan et al., 1993).
The M3 subtype, also known as acute promyelocytic leukemia (APL), is a form of AML
occurring in 5% of all leukemia cases.

APL demonstrates a specific chromosomal

translocation t(15:17) that results in a gene fusion of the retinoic acid receptor alpha
(RARα) with the promyelocytic leukemia gene (PML) denoted as the PML-RARα
translocation. This translocation was reported in 98% of APL patients and was not
observed in other FAB subtypes. Additionally, this PML-RARα gene fusion allows for
APL cells to be susceptible to ATRA as a differential treatment, resulting in a remission
rate of over 90% (Lohse et al., 2018) In non-ATRA treated APL, the PML-RARα protein
binds to a co-repressor preventing the expression of differentiation genes. When APL is
treated with ATRA, the co-repressor is replaced with a co-activator allowing for the
activation and transcription of leukocyte differentiation genes. To date, ATRA research
into other FAB subtypes demonstrates no effect apart from M2 with vitamin-D3
demonstrating a lesser effect than observed in M3 subtype (Johnson & Redner, 2015).

1.2 The recount2 database
Galectin gene expression can be examined using the Cancer Genome Atlas (TCGA)
database. The TCGA was created in 2006 by the National Cancer Institute and the National
Human Genome Research Institute to provide a public catalogue of the full spectrum of
genomic changes involved in human cancers. To date, there are over 20,000 primary
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Figure 1: Hematopoiesis of myeloid origin cells related to the French-AmericanBritish classification system of acute myeloid leukemia.

Figure 1: Hematopoiesis of myeloid origin cells related to the French-AmericanBritish classification system of acute myeloid leukemia.
AML is classified into eight different molecular subtypes depicted as M0-M7 based on
the originating cancerous cell. Leukemias are classified based on the maturation of the
cell type within their related lineage. This figure is adapted from Agarwal et al. (2019).
Subtype identification is performed through light microscopy of nuclear morphology, as
well as genetic abnormalities and biomarkers.
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cancers characterized, including AML. However, accessing AML TCGA data does not
provide a normal control sample with which to compare. AML TCGA data can be obtained
from the recount2 database where healthy bone marrow samples can also be investigated.
The recount2 database provides access to 2041 different studied systems. Recount2 obtains
raw RNA-seq data of various other databases, including TCGA and the Common Fund’s
Genotype-Tissue Expression (GTEx) program. Recount2 normalizes the data following the
protocol detailed by Nellore et al. (2016) and was verified by Collado-Torres et al. (2017).
This normalization technique allows for the comparison of RNA-seq data from different
databases, eliminating computational batch effects. Recount2 normalized both AML
TCGA data and bone marrow samples from the GTEx database, allowing for the
expression profiles of galectins to be examined. FAB subtypes of AML TCGA data can
also be determined from recount2, allowing for galectin gene expression profiling to be
evaluated. However, there are still lab batch effects between the TCGA and GTEx
samples. Risso et al. (2014) demonstrated a differential expression analysis normalization
technique that eliminated the lab batch effect. Empirical control genes are identified
through differential expression analysis of the two datasets. Once analyzed, 500 empirical
control genes are then used to eliminate the variation found between the two datasets,
removing the lab batch effect. This normalization allows for the comparison between
datasets from different databases without variation (Risso et al., 2014).

1.3 HL-60 cells as a model to study cellular differentiation
HL-60 cells were first classified as a M3 subtype in 1976 when isolated from a 36-yearold female acute myeloid leukemia patient and were immortalized in 1977 by the National
Cancer Institute (Collins et al., 1977; Breitman et al., 1980). However, in 1989, HL-60
cells were changed to the M2 FAB classification based on the similarity of morphological
characteristics observed in HL-60 cells and cells of the M2 subtype (Dalton et al., 1988).
HL-60 cells contain a homozygous deletion of the p53 gene, inhibiting G1 cell growth
arrest.

This contributes to continuous proliferation while preventing apoptosis and

differentiation. However, research has shown that normal cell cycle regulation, apoptosis
and differentiation can be restored in HL-60 cells by transfecting cells with p53 (Soddu et
al., 1994).
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In the 1980s, research showed that HL-60 cells can be cultured in the absence of the growth
factors, proteins, and hormones contained in fetal bovine serum (FBS) for in vitro culture.
For the proliferation and survival of HL-60 cells in vitro, a serum-free growth medium
containing insulin, transferrin and selenous acid (ITS) is required (Breitman et al., 1980).
Undifferentiated HL-60 cells contain surface receptors for insulin (insulin receptor, IR) and
transferrin (transferrin receptor, TfR), which allows for binding of these molecules required
for HL-60 cell growth. Insulin is involved with glucose uptake and metabolism, while
transferrin allows for many cellular processes to occur by iron uptake (Breitman et al.,
1980; Chaplinski et al., 1986). Selenous acid provides selenium to cells, which is involved
in redox pathways (Guilbert and Iscove, 1976; McKeehan et al., 1976). To understand
how galectins are involved in the differentiation of HL-60 cells, it is important to culture
in serum-free media due to the galectins present in FBS (Johannes et al., 2018).
HL-60 cells provide a great model to study granulocytic differentiation in relation to AML.
An undifferentiated HL-60 cell is classified as a promyelocyte (pre-leukocyte) and has the
pluripotency to differentiate into various mature leukocyte-like cells including monocytes,
eosinophils, and neutrophils. There are various reagents that induce differentiation of HL60 cells that are well studied. Terminal differentiation into monocytes is achieved by
phorbol 12-myristate 13-acetate, while terminal differentiation into eosinophils is achieved
by sodium-butyrate. However, there are several agents that can be used to induce terminal
differentiation into the neutrophil or granulocyte lineage.
The two main agents used include DMSO and ATRA (Breitman et al., 1980; Abedin et al.,
2003). HL-60 cells have susceptibility to ATRA in the absence of the PML-RARα gene
fusion, found in acute promyeloid leukemia (APL), due to the increased progranulocytes.
The retinoic acid receptor (RARα) for ATRA is found in progranulocytes and once
activated, forms a complex with the retinoid X receptor (RXR) (Breitman et al., 1980;
Tassef et al., 2017).

This ATRA activation results in downstream activation of

transcription factors associated with granulocytic differentiation including C/EBPβ and
PU.1 (Bjerregaard et al., 2003; Akagi et al., 2010; Ai & Udalova, 2019). Additionally, the
ATRA activation also revealed changes in gene expression and activation of proteins
including ERK1/2, p38/MAPK, STAT3, C/EBPα/β, PU.1, integrins, and CD44 (Hickstein
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et al., 1989; Liu et al., 2007; Song et al., 2013; Tasseff et al., 2017) (Figure 2).
Furthermore, previous research with retinoic acid induced differentiation revealed that
changes in galectin gene expression were related to Sp1 consensus binding sites (Lu &
Lotan, 1999; Lu et al., 2000). Therefore, HL-60 cells provide a good model for studying
the effects of galectins during granulocytic differentiation.

1.3.1

Neutrophilic differentiation of HL-60 cells

The innate immune system is made up of many leukocytes including neutrophils.
Neutrophils are effective first responders during microbial infection and are often found in
high amounts in circulation (Kobayashi et al., 2015; Ai & Udalova, 2019). Neutrophils
can have various responses to infections including phagocytosis, release of ROS,
degranulation, and release of nuclear extracellular traps (Kolaczkowska & Kubes, 2013).
There are many aspects that distinguish neutrophils from other innate immune cells and
undifferentiated cells that are reflected in HL-60 cells. Neutrophils have multi-lobular,
segmented nuclei with specific envelope protein composition. This is different relative to
undifferentiated circular nuclei as well as nuclei portrayed by other innate immune cells.
Previous research has reported that HL-60 cells treated with ATRA demonstrate different
stages of nuclear transformation into multi-lobular segmented nuclei specifically observed
in neutrophils (Olins et al., 2000; Veselská et al., 2003; Olins & Olins, 2004).
Additionally, neutrophils produce ROS when interacting with invading microbes through
the NADPH oxidase complex. The NADPH oxidase complex is made up of a group of
proteins that serve as markers for neutrophilic differentiation in HL-60 cells due to the
upregulation observed in mature neutrophils relative to undifferentiated, immature
promyeloid cells (Vinnai et al., 2017; Dakik et al., 2021). The main protein subunits that
make up the NADPH oxidase include neutrophil cytosol factors 1 (NCF1/NOXO2) and 2
(NCF2/NOXA2),

and

cytochrome B

subunits

α (CYBA/P22-PHOX) and

β

(CYBB/NOX2) (Sumimoto, 2008; Belambri at al., 2018). Additionally, previous research
has shown that activation of transcription factors such as C/EBPα/β and PU.1 allow for the
transcription of NCF1/2 as well as other surface markers like CD11b (Tasseff et al., 2017).
Previous research with DMSO-treated HL-60 cells reported that undifferentiated cells
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Figure 2: Schematic of ATRA-induced differentiation in HL-60 cells.
Binding of ATRA to RARα results in activation and formation of the RARα-RXR
complex. Activation of the RARα-RXR complex leads to downregulation of STAT3 and
CD44, and upregulation in PU.1 and C/EBPα/β. Additionally, ATRA activation results
in activation of both ERK1/2 and MAPK pathway. ERK1/2 activation also plays a role
in the global O-GlcNAcylation status of cells. MAPK pathway activation results in PU.1
and C/EBPα/β binding to promoter regions of neutrophil differentiation markers CD11b,
NCF1 and NCF2. This figure was adapted from Tasseff et al. (2017).
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contain higher levels of O-GlcNAcylation relative to differentiation HL-60 cells (Sherazi
et al., 2018). Prior investigations with O-GlcNAcylation and cancer demonstrated that
stem-like cancerous cells also have elevated levels of this cellular protein modification
(Sherazi et al., 2018; Akella et al., 2020) O-GlcNAcylation is a post-translational
modification where an O-linked β-N-acetyl-D-glucosamine (O-GlcNAc) sugar moiety is
added onto the hydroxyl groups of serine and threonine residues of proteins (Yang et al.,
2001; Ferrer et al., 2014; Yang & Qian, 2017; Asthana et al., 2018). This protein
modification is performed by two enzymes: O-GlcNAc transferase (OGT) and OGlcNAcase (OGA). OGT catalyzes the addition of the GlcNAc sugar moiety onto
hydroxyl groups through cleavage of the donor substrate uridine diphosphate Nacetylglucosamine (UDP-GlcNAc). OGA catalyzes the removal of the GlcNAc sugar
moiety (Yang et al., 2001; Ferrer et al., 2014; Yang & Qian, 2017; Asthana et al., 2018).
To obtain the UDP-GlcNAc, cellular respiration needs to occur to obtain fructose-6phosphate. This sugar is used for the hexosamine biosynthetic pathway converting
fructose-6-phosphate into glucosamine-6-phosphate by the enzyme glutamine fructose-6phosphate aminotransferase (GFAT) (Asthana et al., 2018). The final product of the
hexosamine biosynthetic pathway is UDP-GlcNAc (Figure 3). In cancerous cells, OGlcNAcylation status is related to a variety of metabolism-sensing signaling pathways
including MAPK, mTOR, AMPK, ERK1/2, and STAT3 due to the O-GlcNAcylation of
these proteins (Moriwaki & Asahi, 2017; Chang et al., 2020; Wu et al., 2020).

1.4 Galectins
Galectins were first characterized in 1975 as soluble S-type lectins found in the electric eel
Electrophorus electricus (Teichberg et al., 1975). To date, there have been 16 galectin
genes discovered, with 12 being found in humans (Timoshenko, 2015). Galectins were
first separated from other carbohydrate-binding proteins due to their ability to bind glycans
in a calcium-independent manner (Robinson et al., 2019). Galectins have an affinity for βgalactosides through a conserved 130 amino acid sequence called the carbohydrate
recognition domain (CRD) (Johannes et al., 2018). When found extracellularly, galectins
have been reported to be involved in the activation of signal transduction pathways, cellular
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Figure 3: O-GlcNAcylation: a post-translational protein modification.
To obtain UDP-GlcNAc, the cell needs to undergo cellular respiration as well as utilize the
hexosamine biosynthetic pathway. The activity of the GFAT enzyme is the rate limiting
step of this process when converting fructose-6-phosphate to glucosamine-6-phosphate.
The resulting product, UDP-GlcNAc, is used to add the GlcNAc sugar moiety to the
hydroxyl group of serine and threonine residues of proteins through the enzyme OGT.
OGA catalyzes the reverse reaction to remove the GlcNAc sugar moiety. This figure is
adapted from Fardini et al. (2013).
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adhesion, and migration. When found intracellularly in the cytosol, galectins regulate
signal transduction pathways, cellular apoptosis, proliferation, and differentiation.
Additionally, nuclear localized galectins are involved with gene splicing and
transcriptional activation (Johannes et al., 2018). Importantly, galectins often demonstrate
different expression patterns in different cell lines or different tissue types (Liu &
Rabinovich, 2010). Furthermore, both CRD-dependent and CRD-independent functions
have been reported (Tazhitdinova & Timoshenko, 2020).
The CRD structure of galectins allows for the categorization of each protein into one of
three categories: proto-type, tandem-repeat type, and chimeric galectins (Figure 4) (Yang
et al., 2008). Proto-type galectins are characterized by having a single CRD region and
include galectins -1, -2, -5, -7, -10, -11, -13, -14, and -16 (Timoshenko, 2015). This
structure allows these galectins to exist as monomers or homodimers (Nishikawa & Suzuki,
2018). Tandem-repeat type galectins are characterized by having two different CRD
regions found on either end of the protein connected by a non-CRD linker region (Yang et
al., 2008). These galectins are larger than other galectins and include galectins -4, -8, -9,
and -12 (Liu & Rabinovich, 2010).

These galectins can be found as monomers,

homodimers, and heterodimers (Sciacchitano et al., 2018). There is only one chimeric type
galectin characterized to date, galectin-3. Galectin-3 was characterized as having one CRD
region and a proline-rich N-terminal domain (Yang et al., 2008). The structure of galectin3 allows for it to be found as a monomer, homodimer, N-type pentamer, or C-type pentamer
(Nishikawa & Suzuki, 2018).

1.4.1

Galectins in HL-60 cells and AML

Previous research into galectins has documented their role in cancer progression and in
adaptive immunity. However, little is known with respect to their roles in innate immune
cell differentiation and in AML. AML is the most common type of leukemia in adults and
previous RT-qPCR data has determined that there are 8 galectins expressed, including
proto-type galectins -1, -7, and -10, tandem-repeat galectins -4, -8, -9, and -12, and
chimeric galectin -3 (El Leithy et al., 2015; De Kouchkoveky & Abdul-Hay, 2016; Su,
2018). Previous RT-qPCR research also indicates that there are 6 galectins expressed in
the HL-60 cell line including galectins -1, -3, -8, -9, -10, and -12 (Abedin et al., 2003;
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Figure 4: The CRD structure of galectins.
Galectins are classified based on their carbohydrate recognition domains (purple and blue),
linker domain (yellow), and N-terminal domain (green). Proto-type galectins contain one
CRD. Tandem-repeat type galectins contain two different CRDs (found on the C- and Ntermini), connected by a linker peptide region. The chimeric type includes galectin-3
which contains one CRD domain and one N-terminal domain. This figure is adapted from
Timoshenko (2015).
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Timoshenko et al., 2016; Vinnai et al., 2017). Previous research with HL-60 cells has
indicated that galectin gene expression and protein levels change during induced
granulocytic differentiation (Abedin et al., 2003; Timoshenko et al., 2016; Vinnai et al.,
2017; Vakhrusnev et al., 2018). Additionally, it has also been reported that galectins play
a variety of roles in neutrophil function in vitro and in vivo (Abedin et al., 2003; Liu &
Rabinovich, 2009; Robinson et al., 2019). HL-60 cells provide a good model to investigate
the effects of galectins during granulocytic differentiation of HL-60 cells with relation to
the M2 and M3 molecular subtypes of AML.

1.4.2
1.4.2.1

Proto-type galectins and cellular differentiation
Galectin-1

Galectin-1 was the first galectin to be identified and has been extensively investigated due
to its role in cellular differentiation, cancer progression, and immune cell function.
Galectin-1 is a proto-type galectin that promotes the differentiation of early hematopoietic
stem cells (HSCs), trophoblast stem cells, muscle cells and many others (Vas et al., 2005;
Chan et al., 2009; Tang et al., 2018). However, the direct role of galectin-1 in granulocytic
differentiation of HL-60 cells has not been examined. The expression of galectin-1 in
undifferentiated HL-60 cells is well documented. However, depending on the stimuli used,
galectin-1 expression varies in neutrophil-like differentiated cells (Abedin et al., 2003;
Timoshenko et al., 2016; Vinnai et al., 2017; Vakhrusnev et al., 2018). There are two
stimuli that can be used for induced granulocyte differentiation of HL-60 cells: dimethyl
sulfide (DMSO) and all-trans retinoic acid (ATRA). DMSO-induced differentiated cells
exhibit constant expression of galectin-1 (Abedin et al., 2003; Timoshenko et al., 2016;
Vinnia et al., 2017), whereas ATRA- induced differentiated cells exhibit a downregulation
in galectin-1 (Vakhrusnev et al., 2018).
Although the expression of galectin-1 has been reported to vary, there are known effects
elicited by galectin-1 on neutrophil function in innate immunity. Galectin-1 was reported
to be involved with the migration of neutrophils in anti-inflammatory states through the
p38/MAPK and PKC pathway. Additionally, galectin-1 has also been reported to activate
the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in primed neutrophils
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(Almkvist et al., 2002; Auvynet et al., 2013). Previous studies into galectin-1 have also
reported induced lysosome release, degranulation, and neutrophil extravasation (Almkvist
et al., 2002; Elola et al., 2005; Ashraf et al., 2018).
Galectin-1 has also been investigated with respect to its role in adaptive immunity.
Galectin-1 was reported to be a suppressor of adaptive immunity through the regulation of
T cell development. Studies have shown that galectin-1 impacts effector T cell viability
through induced apoptotic death, altered cytokine production, and increased survival of
naïve T cells (Teichberg et al., 1975; Levi et al., 1983; Perillo et al., 1995; van der Leij et
al., 2004). Studies have also reported that galectin-1 in plasma cells enhances antibody
production, B cell development and survival, as well as plasma cell differentiation (Rossi
et al., 2006; Tsai et al., 2008; Espeli et al., 2009; Anginot et al., 2013).
In AML, galectin-1 has been reported to be a pro-survival molecule by RAS activation
intracellularly, activating the MAPK pathway through P13K/AKT signaling for continued
cell proliferation (Ruvolo, 2019). Galectin-1 has also been reported to degrade p53 to
further enhance cell survival while also preventing the migration of HSCs in a cancerous
state (Ruvolo, 2019; Ruvolo et al., 2020).

1.4.2.2

Galectin-7 and -10

Galectin-7 is a proto-type galectin that is not well documented with respect to its role in
granulocytic differentiation or neutrophil function. Previous research with HL-60 cells has
revealed no expression of galectin-7 in this model (Abedin et al., 2003). However, in breast
cancer cells, galectin-7 allows for cancer progression by impairing p53 function (Wang et
al., 2018).

Additionally, in colorectal cancer and sunburnt keratinocytes, galectin-7

exhibits p53 induced apoptosis, which indicates that galectin-7 is a pro-apoptotic protein
(Polyak et al., 1997; Bernerd et al., 1999).
Galectin-10 is the last proto-type galectin found in HL-60 cells and was originally referred
to as Charcot-Leyden crystal protein.

It was initially defined as part of the

lysophopholipase family in 1853 due to lysophospholipase binding (Su, 2018). Once the
Charcot-Leyden crystal protein gene was sequenced and a crystalized structure obtained,
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it became apparent that it resembled the secondary structures of the CRD of galectins,
contained no lysophospholipase activity and was promptly renamed (Mastrianni et al.,
1992; Ackerman et al., 1993; Leffler et al., 2002).
Previous research with HL-60 cells has demonstrated that cells induced to differentiate
with DMSO have upregulated galectin-10 (Abedin et al., 2003; Timoshenko et al., 2016;
Vinnai et al., 2017). Furthermore, Kubach et al. (2007) reported that galectin-10 had an
important role in the suppressed function of T regulatory cells. Additionally, accumulated
galectin-10 crystals in allergic reactions and in parasitic infections is associated with
hypereosinophilia (Ackeman et al., 1993). It was then proposed that galectin-10 had a
regulatory role in eosinophil function (Arthur et al., 2014). To date, both galectin-7 and
galectin-10 have had no investigations to their relations to AML.

1.4.3

Chimeric type galectin-3 and cellular differentiation

Galectin-3 is the only chimeric galectin known to date and has been studied nearly as much
as galectin-1. Galectin-3 has demonstrated roles in immune cell function and cancer
progression. It is well documented that HL-60 cells express galectin-3, and that galectin3 expression is upregulated during DMSO-induced granulocytic differentiation (Abedin et
al., 2003; Timoshenko et al., 2016; Vinnai et al., 2017). Neutrophils also have elevated
levels of galectin-3 (Robinson et al., 2019). Galectin-3 is found in circulation (20-313
ng/mL) which results in the activation of various immune cell functions (Iurisci et al.,
2000). Furthermore, it is often found at elevated levels in cancerous conditions (Iurisci et
al., 2000; Eliaz, 2013).

Secreted galectin-3 has been reported to interact with

immunoglobin E (IgE) and the IgE receptor, which activates the NADPH-oxidase complex
in neutrophils during pro-inflammatory responses and when exposed to gram-negative
bacteria (Sundqvist et al., 2018; Robinson et al., 2019). Additionally, galectin-3 signaling
through carcinoembryonic antigen related cell adhesion molecules (CD66a and CD66b)
also results in the production of reactive oxygen species (ROS) (Robinson et al., 2019).
Galectin-3 has also been reported to be involved with neutrophil response to infection by
Candida

albicans,

Streptococcus

pneumoniae,

and

Aspergillus

fumigatus

by

extravasation., recruitment, and ROS production (Nieminen et al., 2008; Wu et al., 2017;
Snarr et al., 2020). Additionally, inhibition of galectin-3 results in a reduction in various
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cytokine and chemokine levels, as well as decreased neutrophil accumulation. This
indicates that galectin-3 facilitates neutrophil extravasation (Pan et al., 2018).
Galectin-3 has also been shown to be involved in other immune system functions. Previous
studies have reported that galectin-3 elicited increased calcium flux to induce apoptosis
and decrease interleukin 5 secretion in T cells. This affected T cell viability, activation,
and differentiation (Cortegano et al., 1998; Stowell et al., 2008). Additionally, AcostaRodrígues et al. (2004) reported that galectin-3 elicited interleukin 4induced T cell
differentiation and survival.
Previous research with galectin-3 has revealed relationships to AML prognosis, subtype
identification, and patient age (Cheng et al., 2013).

When looking at the AML

microenvironment, mesenchymal stromal cells (MSCs) had elevated level of galectin-3
protein positively correlated with the expression of MYC, β-catenin, and AKT2.
Suppression of galectin-3 also results in a reduction of MYC expression (Ruvolo et al.,
2018). Galectin-3 also exhibits inhibitor effects on immune cell surveillance through
MSCs binding of CD45 and T cell receptors, suppressing T cell function (Ruvolo, 2016).
When looking at the microenvironment of acute leukemia cells, galectin-3 also enabled
drug-resistance through the Wnt/β-catenin pathway (Hu et al., 2015). Galectin-3 also has
activity in mitosis through its binding with the nuclear mitotic apparatus protein (NuMa)
during daughter cell DNA separation (Magescas et al., 2017).

1.4.4
1.4.4.1

Tandem-repeat type galectins and cellular differentiation
Galectin-4 and -8

Galectin-4 is a tandem-repeat galectin often associated with intestinal inflammation that is
not as well documented in the regulation of neutrophils (Timoshenko, 2015). Previous
research with HL-60 cells indicates no expression of galectin-4 in undifferentiated or
differentiated cells (Abedin et al., 2003). However, galectin-4 is proposed to play a role in
the oxidative burst of neutrophils (Huflejt & Leffler, 2004). Additionally, galectin-4
exhibited pro-inflammatory activity by inducing interleukin6 production and CD4+ T cells
activation (Hokama et al., 2004). To date, little is known to the role of galectin-4 in AML,
with its expression being upregulated in younger AML patients (El Leithy et al., 2015).
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Galectin-8 is another tandem-repeat type galectin that demonstrates constant, unchanged
gene expression in HL-60 cells during DMSO-induced granulocytic differentiation
(Abedin et al., 2003; Timoshenko et al., 2016; Vinnai et al., 2017). Galectin-8 has been
reported to stimulate ROS production in neutrophils through binding of its CRD C-terminal
domain to integrin-αM (Nishi et al., 2003). Galectin-8 also aids in neutrophil adhesion to
endothelial cells through integrin-αM, indicating that galectin-8 has a role in regulating
neutrophil extravasation (Yamamoto et al., 2008; Liu & Rabinovish, 2010). Additionally,
thrombin mediated cleavage of galectin-8 nullifies neutrophil adhesion during the
inflammatory response (Esmon et al., 2005).
The role of galectin-8 in adaptive immunity is better understood. T cell proliferation and
apoptosis of activated T cells has been reported to be induced by galectin-8 (Norambuena
et al., 2009; Tribulatti et al., 2012). Tsai et al. (2011) also reported that galectin-8 plays a
role in B cell differentiation, with knockdown inhibition resulting in inhibited plasma cell
differentiation and decreased antibody production.
Galectin-8 has been detected in patients with AML. However, the role of galectin-8 in
AML has not been elaborated upon (El Leithy et al., 2015). In colon cancer, galectin-8 has
been observed to have lower concentrations when compared to healthy cells, (Nagy et al.,
2002).

Additionally, elevated levels of galectin-8 serve as an enhancer for cancer

progression in prostate and breast cancer (Genetilini et al., 2017; Trebo et al., 2020).

1.4.4.2

Galectin-9 and -12

Galectin-9 is a tandem-repeat type galectin that is expressed in HL-60 cells. Previous
research with HL-60 cells indicates that galectin-9 expression is constant during DMSOinduced granulocytic differentiation (Abedin et al., 2003; Timoshenko et al., 2016; Vinnai
et al., 2017). Galectin-9 has been reported to be involved with neutrophil degranulation
and ROS production by binding to T-cell immunoglobin domain and mucin domain 3
(Tim-3) (Vega-Carrascal et al., 2014; Steichen et al., 2015; Robinson et al., 2019).
Furthermore, galectin-9 binding to Tim-3 resulted in IL-8 production, regulating neutrophil
recruitment (Vega-Carrascal et al., 2011; Hirao et al., 2015).

Additionally, surface

galectin-9 was highly expressed in the neutrophils of healthy individuals and was
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downregulated once neutrophils were activated (Dunsmore et al., 2021). Furthermore,
investigation into adaptive immunity has shown that galectin-9 regulates T cell viability
through apoptosis in a Tim-3 dependent manner (Kashio et al., 2003; Zhu et al., 2005).
Interest into the role of galectin-9 in AML stems from to its interaction with Tim-3.
Previous research revealed that the activation of Tim-3 by galectin-9 allows for cancer
progression through evasion from the immune system. Additionally, activation of protein
kinase C and the mTOR pathway allows for increased expression and secretion of Tim-3
and galectin-9 resulting in the apoptosis of natural killer cells, decreased T cell activating
cytokine interleukin 2, and a reduction in T cell viability through apoptosis (Gonçalves
Silva et al., 2017). Furthermore, the blocking of galectin-9 binding to Tim-3 in AML
prevented the reconstitution, self-renewal, and leukemic burden in a mouse transplant
model (Kikushige et al., 2015)
Galectin-12 is another tandem-repeat type galectin that is located primarily in adipocytes
and leukocytes (Yang et al., 2001). Previous research has reported that galectin-12 is
expressed in HL-60 cells and is downregulated upon DMSO-induced granulocyte
differentiation (Vinnai et al., 2017). High levels of galectin-12 increased adipocyte
differentiation and played a critical role in lipolysis adipocyte signaling (Yang et al., 2004).
In ATRA-induced differentiated NB4 cells, knockdowns of galectin-12 resulted in
enhanced neutrophilic differentiation and high production of ROS (Xue et al., 2016). In
AML, Zheng et al. (2019) demonstrated that galectin-12 gene expression is upregulated in
the M3 subtype. Helbawi et al. (2021) also reported that the methylation status of the
galectin-12 gene was related to patient outlook.

1.5 Overarching hypothesis and objectives
Galectins have been extensively investigated with respect to their roles in cellular
differentiation, immune cell functions, and cancer progression. However, little is known
with respect to the role of galectins in the differentiation of myeloid cells and AML.
Previous research has shown that there are changes in galectin gene expression during
DMSO and ATRA induced granulocytic differentiation of HL-60 cells. When looking at
the galectins expressed in HL-60 cells, DMSO and ATRA induced differentiation resulted
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in an upregulation of galectin-3 and -10, and a downregulation of galectin-1 and -12
depending on the stimuli used. Galectin-8 and galectin-9 have shown constant expression
during differentiation of HL-60 cells (Abedin et al., 2003; Timoshenko et al., 2016; Vinnai
et al., 2017). Furthermore, little is understood with respect to galectin gene changes in
AML cells relative to healthy bone marrow cells, and the relationships galectins have with
the differentiation of innate immune cells.
For these reasons, I tested the hypothesis that galectins are essential regulators of
neutrophilic differentiation of promyelocytic HL-60 cells and define phenotypic
differences between subtypes of acute myeloid leukemia. The rationale behind this study
is that galectins demonstrate variable expression patterns during DMSO and ATRA
induced granulocytic differentiation of HL-60 cells. By using recombinant galectins and
galectin inhibitors (OTX008, GB1107, thiodigalactoside), I assessed the role of galectins
in neutrophilic differentiation in the absence and presence of ATRA. Additionally, an in
silico analysis of AML TCGA cohorts allowed for the assessment of galectin gene
expression profiles in AML FAB subtypes for diagnostic and prognostic purposes.
Objective 1: To evaluate the effects of proto-type, chimeric-type, and tandem-repeat type
recombinant galectins on markers of neutrophilic differentiation of the HL-60 cell line in
comparison to ATRA-induced responses.
Objective 2: To examine the effects of CRD and non-CRD specific inhibition of galectin1 and galectin-3 on markers of neutrophilic differentiation of the HL-60 cell line in
comparison to ATRA-induced responses.
Objective 3: To perform an in silico analysis on galectin gene expression from the Cancer
Genome Atlas AML patient samples for new FAB subtype diagnostics, prognosis, and to
evaluate changes in the glycobiological landscape.
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Chapter 2

2

Materials and Methods

2.1 Chemicals and solutions
Dulbecco’s Phosphate Buffer Saline (DPBS) without calcium and magnesium (311-424CL), Iscove’s Modification of Dulbecco’s Modifed Eagle Medium (IMDM) (319-105-CL),
and 100x ITS Universal Culture Supplements (315-081-QL) were purchased from Wisent
Bio Products (Saint-Jean-Baptiste, QC).

Fetal Bovine Serum (FBS) (12484-028), and

SYBR™ Safe DNA Gel Stain (s33102) were purchased from ThemoFisher (Mississauga,
ON). All-trans-retinoic acid (ATRA) (R2625), dimethyl sulfide (DMSO) (D26500), and
Immobilon Classico Western HRP substrate (WBLUC500) were purchased from SigmaAldrich Canada (Oakville, ON). Recombinant human galectin-1 animal-free protein
(NBP2-76255-50ug), recombinant human galectin-3 protein (NBP2-34881-50ug), and
recombinant human galectin-8 protein (NBP1-48335-0.05mg) were purchased from BioTechne (Kanata, ON). Recombinant human galectin-9 protein (2045-GA) was purchased
from R&D Systems (Oakville, ON). GB1107 (HY-114409), and OTX008 (HY-19756)
were kindly provided from MedChemExpress (Burlington, ON). Thiodigalactoside (TDG)
(OG05033) was purchased from Carbosynth Ltd (San Diego, CA). Brefeldin A (11861)
was purchased from Cayman Chemicals (Ann Arbor, MI). Bovine serum albumin (BSA)
(AD0023), mammalian Protease Inhibitor Cocktail (BS386), sodium azide (NaN3)
(S2002), (AD0023), sodium orthovanadate (Na3VO4) (SB0869), and 2x RIPA Buffer IIII
with EDTA and EGTA (pH 7.4) (RB4477) were purchased from BioBasic (Markham,
ON). Non-fat dry milk blotting-grade blocker (1706404), and SsoAdvanced Universal
SYBR® Green Supermix (1725274) were purchased from Bio-Rad (Mississauga, ON).
TRIzol® (15596018) was purchased from Life Technologies (Toronto, ON).
VECTASHIELD Vibrance Mounting Medium with DAPI (H-1800) was purchased from
Vector Laboratories (Burlingame, CA). Froggarose LE Molecular Biology Grade Agarose
(A87) was purchased from FroggaBio (Concord, ON).
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2.2 Cell culture and treatments
Cell culture – Human acute promyelocytic leukemia HL-60 (ATCC® CCL-240TM) cells
were cultured in suspension with IMDM without antibiotics and sub-cultured to maintain
a cell concentration under 1 x 106 cells/mL in either Ø60 mm (82.1194.500) or Ø100 mm
suspension culture dishes (83.3902.500) from SARSTEDT and grown in a humidified
incubator at 37°C with 5% CO2. IMDM media was supplemented with 1% ITS (5 µg/mL
human insulin, 5 µg/mL human transferrin, 5 ng/L selenous acid) (IMDM-ITS) or 10%
FBS (IMDM-FBS). Cell viability was determined using the trypan blue (0.4%) exclusion
test and was not less than 90%.
Treatment of HL-60 cells with all-trans retinoic acid – Cells concentrated at 4 x 105 – 5 x
105 cells/mL in IMDM-ITS were grown in either Ø60 mm or Ø35 mm (80.1135.500)
suspension culture dishes, 6 well (83.3920.500) plates, 42 well (83.3922.500) plates or 48
well plates (83.3923.500) from SARSTEDT and treated with 1 µM ATRA for 72 h as
described by Gupta et al. (2014) to induce neutrophil-like differentiation.
Treatment of HL-60 cells with recombinant galectins – Cells in IMDM-ITS were treated
with 10 ng/mL, 100 ng/mL and 1000 ng/mL of human recombinant galectin-1, -3, -8 or -9
to determine a dose-dependent effects in the presence or absence of ATRA. Cells treated
with recombinant galectins were plated at a cell concentration of 1 x 105 cells/mL, and cells
treated with recombinant galectins + ATRA were treated at a cell concentration of 4 x105
cells/mL. Cells were also treated with 1000 ng/mL of human recombinant galectin-1, -3,
-8 or -9 daily every 24 h in the presence or absence of ATRA. Cells were also treated with
combinations of 500 ng/mL of human recombinant galectin-1, -3 and/or -8. Cells that were
daily supplemented with recombinant galectins were plated at a concentration of 3 x 105
cells/mL, and ATRA treated cells daily supplemented with recombinant galectins were
plated at a concentration of 6 x 105 cells/mL. Cells were grown in Ø35 mm suspension
culture dishes, 6 well plates, 42 well plates or 48 well plates from SARSTEDT. All
recombinant galectin treatments were over 72 h, and cells grown in a humidified incubator
at 37°C with 5% CO2.
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Treatment of HL-60 cells with CRD and non-CRD inhibitors – Cells in IMDM-ITS were
treated with 5 µM OTX08 (Kd = 30 µM) galectin-1 inhibitor, 2 µM GB1107 (Kd = 37 nM)
(Vuong et al., 2019) galectin-3 inhibitor, or 100 µM TDG broad galectin-1 (Kd = 24 µM)
and -3 (Kd = 48 µM) (van Hattum et al., 2013) inhibitor daily for 72 h. Inhibitor treatment
cells were plated at a concentration of 2.5 x 105 cells/mL, and inhibitor + ATRA treated
cells were plated at a concentration of 5 x 105 cells/mL. Cells were grown in Ø60 mm
suspension culture dishes from SARSTEDT and in humidified conditions at 37°C with 5%
CO2.
Treatment of HL-60 cells with brefeldin A – Cells in IDMD-ITS were plated at a
concentration of 4 x 105 cells/mL in Ø35 mm suspension culture dishes from SARSTEDT.
Cells were treated with 1 µM brefeldin A for 24 h in a humidified incubator at 37°C with
5% CO2.

2.3 Nuclear staining and fluorescence microscopy
To prepare HL-60 cells for nuclear staining, cell concentrations and viability were
determined using hemocytometer and trypan blue (0.4%) exclusion test. Cells were diluted
to 3 x 105 – 5 x 105 cells/mL with DPBS and 200 L of cells were centrifuged onto glass
slides for 5 min at 500 rpm using the Shandon Cytospin 2 centrifuge. Cells were stained
with

4’,6-diamidino-2-phenylindole

(DAPI)-contained

VECTASHIELD

Vibrance

Mounting Medium. An AxioImager A1 fluorescent microscope (Carl Zeiss) with DAPI
filter cube was used to view slides. Images of cells were captured using a high-resolution
monochrome XCD-X700 CCD camera (Sony Corporation) while using the Northern
Eclipse 8.0 software from Empix Imaging (Mississauga, ON). Images of cells were used
to calculate differentiation and apoptotic indices based on nuclear morphology.

2.4 RNA isolation, cDNA synthesis, RT end-point PCR, and
RT-qPCR gene expression
Total mRNA isolation and cDNA synthesis – HL-60 cells were centrifuged for 5 min at 300
x g and washed once with ice-cold DPBS. Total mRNA was isolated from cell pellets
using the TRIzol ® method according to manufacturer’s protocol. The mRNA samples
were resuspended in sterile nuclease-free water and the Thermo ScientificTM Nanodrop
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2000c UV-Vis spectrophotometer was used to determine the A260/280 ratio with a threshold
of >1.8. cDNA was synthesized from mRNA (200 ng – 1 g) using the High-Capacity
cDNA reverse transcription Kit from Applied Biosystems (4368813) following the
manufacturer’s protocol.
Reverse transcription real-time and end-point polymerase chain reaction – All primers for
reverse transcription real-time polymerase chain reaction (RT-qPCR) assays were
synthesized by BioCorp UWO OligoFactory (Western University, ON) and verified by
BLAST (Table S1). End-point PCR amplification was performed using the T100 Thermo
Cycler (Bio-Rad) in 20 µL (1 µM forward primer, 1 µM reverse primer, 1 µL cDNA)
reactions using the 2X Taq FroggaMix (FroggaBio) (FBTAQM). PCR amplicons were
separated on a 2% agarose gel containing SYBR® Safe in TAE buffer (20 mM Tris, 40
mM Acetic Acid, 1.2 mM EDTA) and visualized using a Molecular Imager GelDoc XR+
(Bio-Rad) with Image Lab software V6.0 (Bio-Rad). The SsoAdvanced Universal SYBR®
Green supermix was used for RT-qPCR amplification of samples with 20 µL (1 µM
forward primer, 1 µM reverse primer, and1 µL cDNA) volumes. The CFX ConnectTM
Real-Time PCR Detection System from Bio-Rad was used to quantify mRNA transcripts
by a 2 min at 95°C polymerase activation, followed by a 2-step cycling regime of 40 cycles
of denaturation (5 s, 95°C) and annealing (25 s, 60 - 62°C) (Table S1). Relative transcript
levels were calculated using the Livak method (2-ΔΔ CT) with β-actin (ACTB) as a reference
gene.

2.5 Protein isolation and immunodot blot
Protein isolation – HL-60 cells were centrifuged for 5 min at 300 x g and washed twice
with ice-cold DPBS. Cell pellets were lysed in 50-200 µL of 1X RIPA buffer (50 mM
Tris-HCl, pH 7.5, 0.1% sodium dodecyl sulfate, 0.5% w/v sodium deoxycholate. 5 mM
EGTA

and

150

mM

NaCl)

containing

100

µM

Na3VO4,

1

µM

4-(2-

aminoethyl)benzenesulfonyl fluoride hydrochloride, 100 µM phenylmethylsulfonyl
fluoride, 1.4 µM E-64, 1 mM bestatin, 1 µM leupeptin, 1.5 µM pepstatin A, and 0.08 µM
aprotinin then incubated on ice for 10 min. Cell lysates were centrifuged at 12,000 x g for
12 min at 4°C. Total protein concentrations were determined using the DCTM Protein
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Assay Kit II (5000112) from Bio-Rad with BSA standards. Absorbances were measured
at 655 nm using a model 3550 Miscroplate Reader from Bio-Rad.
Immunodot blot – Nitrocellulose membranes (0.22 mm pore size) from GE Healthcare
(16060006) were prewetted in Tris-buffer saline (TBS) (20 mM Tris-HCl, pH 7.5, 150 mM
NaCl) and then placed on a Bio-Dot® Microfiltration apparatus from Bio-Rad as described
by Sherazi et al. (2018). Each well was loaded with 200 mL of total protein extract (5-12.5
µg/mL in DPBS) and immobilized by gravity filtration for 2 h. Membranes were blocked
with a 3% non-fat dry milk solution in TBST buffer (TBS and 0.05% Tween 20) for 60
min at room temperature. Membranes were washed three times with TBST and incubated
overnight at 4°C with 1:1,000 O-GlcNAc (RL2) mouse monoclonal antibody from
ThermoFisher (MA1-072) in TBST containing 5% BSA and 0.05% sodium azide.
Membranes were washed three times with TBST and then incubated with 1:10,000 goat
anti-mouse polyclonal IgG-HRP conjugated from ThermoFisher (A16066) in TBST
containing 5% non-fat dry milk solution for 1.5 h at room temperature. Membranes were
visualized using 2 mL of Immobilon Classico chemiluminescent reagent from SigmaAldrich (WBLUC0500) as well as the ChemiDoc XRS system with Quantity One Software
V4.6.6.

2.6 Retrieval and RUVg normalization of AML and BM
samples
Genes of interest – Various galectin genes ( galectin-1 (LGASL1), galectin-3 (LGALS3),
galectin-4 (LGALS4), galectin-8 (LAGLS8), galectin-9 (LGALS9), galectin-10 (CLC), and
galectin-12 (LGALS12)) were investigated and compared to different marker genes
(neutrophil cytosolic factor 1 and 2 (NCF1/2), and cytochrome B α and β (CYBA/B), OGlcNAc cycle enzymes (O-GlcNAcase (OGA), O-GlcNAc transferase (OGT), and
glutamine fructose-6-phosphate aminotransferase (GFAT1)), and cell stemness marker
genes (octamer-binding protein 4 (OCT4), nanog homeobox (NANOG), RNA binding Fox1 homolog 2 (FOX2), proto-oncogene (C-MYC), Kruppel like factor 4 (KLF4), and CD34
molecule (CD34)).
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Retrieval of acute myeloid leukemia patient RNA-Seq data – AML patient RNA-Seq by
Expectation Maximization (RSEM) (n=160) data for from The Cancer Genome Atlas
(TCGA) for survival curve analysis was extracted from cBioPortal for cancer genomic
(https://cbioportal.org/) platform and converted to a log2 scale in Microsoft Office Excel
prior to survival curve statistical analysis in GraphPad Prism (V8.01-9.01). Additional
patient data were determined using TCGA biolinks R-package (https://bioconductor.org/)
in R studios. TCGA AML raw RNA-Seq counts (n=126) and Genotype-Tissue Expression
(GTEx) bone marrow raw RNA-Seq counts (n=70) were extracted from recount2
(https://jhubiostatistics.shinyapps.io/recount/) for differential expression analysis. Data
were opened in R studios and TCGA Biolinks R package and Ensembl ID annotation
package were used to determine AML subtype and gene names. Raw RNA-seq counts
were filtered where genes with less than 5 reads between 2 samples were removed from
the data sets. The filter raw RNA-seq data were then upper quartile normalized prior to
RUVg normalization (Nellore et al., 2016; Collado-Torrse et al., 2017).
Removal of unwanted variation (RUVg) – Differential expression analysis between AML
and GTEx was performed to identify 500 least differential expression empirical control
genes for normalization. The RUVg normalization algorithm linear model of Log E [Y|
W, X, O] = Wα + Xβ + O was used where, Y represents the observed matrix of gene-level
counts, W represents the contribution of each factor of unwanted variation to each sample,
α represents the contribution of each factor of unwanted variation to each gene, X
represents the observed matrix stating treatment/condition status, β represents the observed
matrix of treatment/condition effect each gene and O represents the offsets that occur due
to upper quartile normalization. With the assumption that for some genes β = 0, the final
algorithm used was Log E [Y| W, X, O] = Wα + O (Risso et al., 2014). RUVg normalized
data were transferred into Microsoft Office Excel and log2 transformed prior to statistical
analysis in GraphPad Prism (V8.01-9.01).

2.7 In silico analysis
Determination of the distribution of data – D’Agostino & Pearson normality tests and
Shapiro-Wilk normality tests were conducted prior to statistical analysis to determine the
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distribution of the data. Based on the results of the normality tests, non-parametric analysis
was conducted for all statistical tests.
Differential expression analysis – For comparison between normal bone marrow samples
and all cohorts of AML data, non-parametric Mann-Whitney U test was performed to
determine corresponding P-values. For comparison between normal bone marrow samples
and FAB subtype classification of M0-M5 AML, non-parametric Kruskal-Wallis test with
Dunn’s multiple comparisons tests were performed to determine corresponding P-values.
The data were presented as means ± SD and as violin plots. Log2 fold changes (log2FC)
were calculated using mean log2 normalized RNA-Seq data where a log2FC of zero
represents no change in gene expression with bone marrow serving as a normal control.
Correlation analysis – Pairwise, non-parametric Spearman’s correlation analysis was
performed in GraphPad Prism (V8.4.3) to determine corresponding correlation coefficient
(ρ) and P-values in both bone marrow and AML cohorts. To determine significant
differences in gene expression correlation patterns between bone marrow and AML
cohorts, the comparing correlations (cocor) R package was used in R studios implementing
Fisher’s z-transformation of correlation coefficients for comparison between independent
groups (Diedenhofen & Much, 2015).

The data were presented in heat maps and

comparison table.
Survival curve analysis – Survival curve analysis was conducted for all RSEM AML
cohorts from cBioPortal as well as the FAB subtype classification M0-M5 for galectin gene
and O-GlcNAc cycle related enzymes using the log-rank (Mantel-Cox) test.

2.8 Statistical Analysis
Unpaired Student’s t-test, One-way ANOVA with Tukey’s multiple comparison test, and
Two-way ANOVA with Tukey’s multiple comparison test were performed using
GraphPad Prism V8.01 and V9.01 for Windows (GraphPad Software, La Jolla CA,
www.graphpad.com). All experiments were performed using a minimum of three
biological replicates. Data were presented as means ± SD and differences between means
were considered significant at p<0.05.
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Chapter 3

3

Results

3.1 The impact of galectins on differentiation of HL-60 cells
3.1.1

Hallmarks of all-trans retinoic acid-induced neutrophilic
differentiation of HL-60 cells

Acute promyeloid leukemia HL-60 cells served as a model system to understand
granulocyte differentiation in the context of AML. All-trans retinoic acid (ATRA) has
been used in various studies and cell models for promyeloid cell induced differentiation
into granulocytes. Previous research with HL-60 cells demonstrated that 1 µM ATRA
induced high levels of granulocytic differentiation over 72 hours (Gupta et al., 2014). In
this study, the degree of differentiation induced by ATRA in an HL-60 cell model was
assessed. Nuclear morphology, neutrophil cytosolic factor 1 (NCF1) gene expression, and
global O-GlcNAcylation are several characteristics that change due to stimuli induced
differentiation of HL-60 cells (Olins & Olins, 2004; Vinnai et al., 2017; Sherazi et al.,
2018).
Upon ATRA-induced differentiation, the nuclear morphology of HL-60 cells was
examined using DAPI staining. Over 72 hours, untreated HL-60 cells exhibited circular
morphology and ATRA-induced differentiated HL-60 cells exhibited multi-lobular,
segmented nuclei (Figure 5A).

Upon quantification, ATRA-induced HL-60 cells

exhibited 87.4% (± 0.2%) segmented nuclei relative to untreated cells (2.4 ± 0.6%,
p<0.0001) (Figure 5B). Vinnai et al. (2017) reported that DMSO-induced differentiated
HL-60 cells had an upregulation in NCF1 expression by RT-qPCR. In this study, ATRAinduced differentiated HL-60 cells also caused an upregulation in NCF1 expression of
178.6-fold relative to untreated cells (p<0.0001) (Figure 5C). Sherazi et al. (2018)
reported that DMSO-induced differentiation of HL-60 cells also caused a decrease in
global O-GlcNAcylation by immunodot blot assay.

In this study, ATRA-induced

differentiated HL-60 cells also caused a decrease in global O-GlcNAcylation of 57%
relative to untreated cells (p<0.01) (Figure 5D).
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Figure 5: ATRA-induced granulocytic differentiation of HL-60 cells.
HL-60 cells were treated with 1 µM ATRA to induce granulocytic differentiation for 72 h.
(A) HL-60 cell nuclear morphology visualized by DAPI stain demonstrated
undifferentiation promyeloid cells (white arrow) and abnormal, multi-lobular granulocytelike differentiated cells (red arrow), with example nuclei found in the top left corners. Scale
bar represents 20 µm. (B) The differentiation index was determined as the percent of nuclei
demonstrating segmented, multi-lobular granulocyte-like shape of 100 – 400 cells counted.
(C) Granulocyte specific genes NCF1 was quantified by RT-qPCR with the Livak Method
(2-∆∆Ct) using ACTB as an internal control.

(D) O-GlcNAcylation was assessed by

immunodot blot using the RL2 antibody. Data are presented as the mean ± SD, n=3.
Significant differences were determined using unpaired Student’s t-test. **p<0.01,
****p<0.0001.
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3.1.2

The effects of proto-type recombinant galectin-1 and
galectin-1 inhibitors on differentiation of HL-60 cells

Galectin-1 is one of the 6 galectins expressed in HL-60 cells that were previously
investigated by Vinnai et al. (2017). However, the impact galectin-1 has on granulocytic
differentiation of HL-60 cells is unknown. The dose-dependent effects of 10, 100 or 1000
ng/mL of human recombinant galectin-1 on HL-60 cells differentiation over 72 hours was
assessed. Galectin-1 treated cells exhibited no significant changes in the percentage of
segmented nuclei at all concentrations (3.5 ± 0.4, 3.0 ± 0.9, and 3.8 ± 1.3% respectively)
relative to untreated cells (3.5±1.0 %) (Figure 6A-B). Galectin-1 dose-dependent treated
cells also had no significant change in the regulation of NCF1 at all concentrations (0.8fold, 0.9-fold, and 1.3-fold, respectively) relative to untreated cells (Figure 6D).
Additionally, HL-60 cells treated with 1000 ng/mL of recombinant galectin-1 had no
significant decrease in global O-GlcNAcylation (16.6%) relative to untreated cells (Figure
6F).
To further evaluate the effects of recombinant galectin-1, daily supplementation with 1000
ng/mL for 72 hours was conducted. Daily supplementation with galectin-1 exhibited no
significant change in the percentage of segmented nuclei (1.3 ± 0.6%) compared to
untreated cells (1.1 ± 0.5%) (Figure 7A-B). Furthermore, there was no significant changes
in the regulation of NCF1 (2.7-fold) relative to untreated cells (Figure 7D). Global OGlcNAcylation demonstrated no significant change (105.7%) when treated with 1000
ng/mL galectin-1 relative to untreated cells (Figure 7E).
Combination treatments with 1 µM ATRA were also conducted with dose-dependent (10,
100 and 1000 ng/mL) and daily supplementation (1000 ng/mL) of recombinant galectin-1.
Dose-dependent treatments with galectin-1 + ATRA demonstrated no significant change
in the percentage of segmented nuclei with 10 ng/mL (85.4 ± 2.5%).

However, a

significant increase was observed with 100 ng/mL (88.5 ± 1.9%, p<0.01) and 1000 ng/mL
(86.4 ± 1.3%, p<0.05) in the percentage of segmented nuclei relative to ATRA treated cells
(80.9 ± 1.9 %) (Figure 6A, C). Furthermore, there were no significant changes in the
expression of NCF1 with galectin-1 + ATRA treated cells at all concentrations (68.9-fold,
72.2-fold, and 94.1-fold, respectively) relative to ATRA treated cells (44.9-fold) (Figure
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Figure 6: Dose-dependent effects of human recombinant galectin-1 on granulocytic
differentiation of HL-60 cells.
HL-60 cells were treated with 10, 100, or 1000 ng/mL of galectin-1, with half the cells also
being treated with 1 µM ATRA to induce granulocytic differentiation for 72 h. (A) Nuclear
morphology of control and galectin-1 treated cells were visualized by DAPI staining with
the scale bar representing 20 µM. The differentiation index was determined as the
percentage of nuclei demonstrating multi-lobular granulocyte-like shape based on galectin1 (130 – 205 cells counted) (B) and galectin-1+ATRA (150 – 360 cells counted) treatments
(C). Granulocyte specific gene NCF1 was quantified by RT-qPCR with the Livak Method
(2-∆∆Ct) using ACTB as an internal control for galectin-1 (D) and galectin-1+ATRA
treatments (E). (F) O-GlcNAcylation was assessed by immunodot blot using the RL2
antibody when HL-60 cells were treated with 1000 ng/mL galectin-1 ± ATRA. Data are
presented as mean ± SD, n=3-4. Significant differences were determined using One-way
ANOVA and Two-way ANOVA followed by Tukey’s HSD test and are represented as
different letters with a p<0.05.
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Figure 7: Daily supplementation effects of human recombinant galectin-1 on
granulocytic differentiation of HL-60 cells.
HL-60 cells were supplemented daily with 1000 ng/mL of galectin-1, with half the cells
being treated with 1 µM ATRA for 72 h. (A) Nuclear morphology of control and galectin1 treated cells were visualized by DAPI staining with the scale bar representing 20 µM.
The differentiation index was determined as the percentage of nuclei demonstrating multilobular granulocyte-like shape based on galectin-1 (150 – 300 cells counted) (B) and
galectin-1 + ATRA (190 – 280 cells counted) treatment (C). (D) Granulocyte specific gene
NCF1 was quantified by RT-qPCR with the Livak Method (2-∆∆Ct) using ACTB as an
internal control for galectin-1 and galectin-1 + ATRA treatments. (D) O-GlcNAcylation
was assessed by immunodot blot using the RL2 antibody of galectin-1 ± ATRA treatments.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and Two-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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6E). Additionally, global O-GlcNAcylation demonstrated no significant changes (46.5%)
when treated with 1000 ng/mL of galectin-1 + ATRA compared to ATRA treated cells
(39.4%) (Figure 6F). The ATRA treatment for the dose dependent concentrations with
galectin-1 + ATRA demonstrated an increase in the percentage of segmented nuclei
(p<0.0001), upregulation in NCF1 expression (p<0.05) and decrease in global OGlcNAcylation (p<0.05) relative to untreated HL-60 cells (Figure 6A-F).
Daily supplementation of 1000ng/mL of galectin-1 + ATRA exhibited no significant
change in the percentage of segmented nuclei (76.2 ± 4.2%) relative to ATRA treated cells
(81.8 ± 6.4%) (Figure 7A, C). However, an upregulation in the expression of NCF1 was
detected with galectin-1 + ATRA treated cells (131.6-fold) relative to ATRA treated cells
(61.0-fold, p<0.01) (Figure 7D). Furthermore, global O-GlcNAcylation demonstrated no
significant change with 1000 ng/mL of galectin-1 + ATRA treatment (80.1%) compared to
ATRA treated cells (67.4%) (Figure 7E).

The ATRA treatments for the daily

supplementation with galectin-1 + ATRA demonstrated an increase in the percentage of
segmented nuclei (p<0.0001), upregulation in NCF1 expression (p<0.01), and a decrease
in global O-GlcNAcylation (p<0.0001) relative to untreated cells (Figure 7A-E).
During ATRA-induced differentiation, galectin-1 expression in HL-60 cells is
downregulated (Vakhrushev ert al., 2018). Therefore, the galectin-1 specific allosteric
inhibitor OTX008 and the galectin broad inhibitor TDG were investigated. HL-60 cells
were treated with 5 µM OTX008 or 100 µM TDG daily over 72 hours. OTX008
demonstrated a significant increase in segmented nuclei (12.3 ± 1.9%) relative to DMSO
vehicle control (8.8 ± 1.7%, p<0.05) and untreated cells (2.3 ± 0.7%, p<0.0001) (Figure
8A-B). Furthermore, a significant upregulation in NCF1 expression was also observed
with OTX008 treatment (26.7-fold) relative to DMSO vehicle control (12.8-fold, p<0.05)
and untreated cells (p<0.001) (Figure 8D). Additionally, a significant global decrease in
O-GlcNAcylation was observed with OTX008 treatment (91.7%) relative to DMSO
vehicle control (49.3%, p<0.01) and untreated cells (p<0.0001) (Figure 8F-G). However,
daily treatments with galectin broad inhibitor TDG demonstrated no significant effect on
granulocytic differentiation of HL-60 cells.

Nuclear morphology demonstrated no

significant change in the percentage of segmented nuclei (4.1 ± 0.4%) compared to
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Figure 8: Allosteric inhibition of galectin-1 with OTX008 induces granulocytic
differentiation of HL-60 cells not observed with TDG.
HL-60 cells were supplemented daily with either 5 µM OTX008, 100 µM thiodigalactoside
(TDG), or 0.467% (v/v) DMSO as vehicle control, with half the cells treated with 1 µM
ATRA for 72 h. (A) Nuclear morphology of untreated and treated cells were visualized by
DAPI staining with the scale bar representing 20 µM. The differentiation index was
determined as the percentage of nuclei demonstrating multi-lobular granulocyte-like shape
based on OTX008 and TDG treatments (120 – 210 cells counted) (B), and OTX008 +
ATRA (130 – 250 cells counted) and TDG + ATRA (120 - 240 cells counted) treatments
(C). Granulocyte specific gene NCF1 was quantified by RT-qPCR with the Livak method
(2-∆∆Ct) using ACTB as an internal control for OTX008 and TDG treatments (D), and
OTX008 + ATRA and TDG + ATRA treatments (E). (F) O-GlcNAcylation was assessed
by immunodot blot using the RL2 antibody for OTX008 and TDG treatments (G), and
OTX008 + ATRA and TDG + ATRA treatments (H). Data are presented as mean ± SD,
n=3-5. Significant differences were determined using One-way ANOVA followed by
Tukey’s HSD test and are represented as different letters with a p<0.05.
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untreated cells (2.3 ± 0.7%) (Figure 8A-B). Furthermore, there was no significant change
in the expression of NCF1 (0.9-fold) or in global O-GlcNAcylation (12.9%) when
compared to untreated cells (Figure 8D, F-G).
To further understand the effects of OTX008 and TDG on granulocytic differentiation of
HL-60 cells, combination treatments with 1 µM ATRA were conducted with daily
treatments of 5 µM OTX008 or 100 µM TDG for 72 hours. Daily treatments of OTX008
+ ATRA demonstrated a significant decrease in segmented nuclei (62.3 ± 6.2%) relative to
DMSO vehicle control (77.8 ± 1.3%, p<0.05) and ATRA treated cells (76.5 ± 2.8%,
p<0.05) (Figure 8A, C). When examining NCF1 expression, there was no significant
change in OTX008 + ATRA treated cells (251.1-fold) relative to DMSO vehicle control
(235.4-fold). However, the OTX008 treatment demonstrated an upregulation of NCF1
relative to ATRA treated cells (75.7-fold, p<0.05).

The DMSO vehicle control

demonstrated no significant change in NCF1 expression relative to ATRA treated cells
(Figure 8E). Additionally, global O-GlcNAcylation had no significant change with
OTX008 + ATRA treatment (69.4%) relative to DMSO vehicle control (59.4%), and
ATRA treated cells (34.2 %) (Figure 8F, H). The ATRA treatment with OTX008 + ATRA
demonstrated an increase in the percentage of segmented nuclei (p<0.0001), upregulation
of NCF1 expression (p<0.0001), and decrease in global O-GlcNAcylation (p<0.05)
relative to untreated cells (Figure 8A-H).
Combination treatments of TDG + ATRA demonstrated no significant effect on
granulocytic differentiation of HL-60 cells. TDG + ATRA demonstrated no significant
change in the percentage of segmented nuclei (76.5 ± 7.6%) relative to ATRA treated cells
(76.5 ± 2.8%,) (Figure 8A, C). Additionally, TDG + ATRA demonstrated no significant
change in NCF1 expression (83.4-fold) and global O-GlcNAcylation (15.46%) relative to
ATRA treated cells (75.7-fold and 34.2 %, respectively) (Figure 8E-F, H).

3.1.3

The effects of chimeric type recombinant galectin-3 and a
galectin-3 inhibitor on differentiation of HL-60 cells

Galectin-3 is another galectin expressed in HL-60 cells reported by Vinnai et al. (2017),
that demonstrated upregulation during differentiation. The dose-dependent effects of 10,
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100 or 1000 ng/mL human recombinant galectin-3 on HL-60 cell differentiation for 72
hours was thus assessed. Nuclear morphology exhibited no significant changes in the
percentage of segmentation for 10 ng/mL (1.8 ± 0.6%) and 100 ng/mL (1.6 ± 0.4%) treated
cells, whereas 1000 ng/mL treated cells exhibited an increase in the percentage of
segmented nuclei (3.6 ± 0.5%, p<0.01) relative to untreated cells (1.8 ± 0.3%) (Figure 9AB). Furthermore, there were no significant changes observed in the regulation of NCF1 at
all concentrations (0.9-fold, 0.9-fold, and 1.1-fold, respectively) relative to untreated cells
(Figure 9D). Additionally, there were no significant changes observed in the global OGlcNAcylation of the cells treated with 1000 ng/mL of galectin-3 (19% increase) relative
to untreated cells (Figure 9F).
To provide a further understanding of the effects of galectin-3 on granulocytic
differentiation of HL-60 cells, cells were supplemented daily with 1000 ng/mL of galectin3 for 72 hours. Nuclear morphology exhibited no significant changes in the percentage of
segmented nuclei when supplemented daily with galectin-3 (1.8 ± 0.09%) relative to
untreated cells (1.0 ± 0.7%) (Figure 10A-B). Furthermore, there were no significant
changes observed in the expression of NCF1 (0.9-fold) and global O-GlcNAcylation
(19.6%) of galectin-3 daily supplemented cells relative to untreated cells (Figure 10D-E).
To evaluate the effects of galectin-3 on ATRA-induced differentiated HL-60 cells,
combination treatments of 1 µM ATRA and dose-dependent effects (10, 100 and 1000
ng/mL) and daily supplementation (1000 ng/mL) of galectin-3 were conducted for 72
hours. Dose-dependent effects of galectin-3 + ATRA demonstrated no significant effects
in the percentage of segmented nuclei (86.8 ± 0.5, 88.3 ± 0.4, and 85.6 ± 3.4%,
respectively) relative to ATRA treated cells (85.5 ± 2.2%) (Figure 9A, C). Furthermore,
there were no significant changes observed in the expression of NCF1 of galectin-3 +
ATRA treated cells (122.6-fold, 118.3-fold, and 114.9-fold, respectively) relative to ATRA
treated cells (118.1-fold) (Figure 9E). Additionally, there were no significant changes in
global levels of O-GlcNAcylation observed with 1000 ng/mL of galectin-3 + ATRA treated
cells (40.5%) relative to ATRA treated cells (39.4 %) (Figure 9F). The ATRA treatment
for the dose dependent effects with galectin-3 + ATRA demonstrated an increase in the
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Figure 9: Dose-dependent effects of human recombinant galectin-3 on granulocytic
differentiation of HL-60 cells.
HL-60 cells were treated with 10, 100, or 1000 ng/mL of galectin-3, with half the cells also
being treated with 1 µM ATRA to induce differentiation for 72 h. (A) Nuclear morphology
of control and galectin-3 treated cells were visualized by DAPI staining with the scale bar
representing 20 µm. The differentiation index was determined as the percentage of nuclei
demonstrating multi-lobular granulocyte-like shape based on galectin-3 (170 – 360 cells
counted) (B) and galectin-3 + ATRA (230 – 430 cells counted) treatments (C). Granulocyte
specific gene NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using
ACTB as an internal control for galectin-3 (D) and galectin-3 + ATRA treatments (E). (F)
O-GlcNAcylation was assessed by immunodot blot using the RL2 antibody when HL-60
cells were treated with 1000 ng/mL galectin-3 ± ATRA. Data are presented as mean ± SD,
n=3-4. Significant differences were determined using One-way ANOVA and Two-way
ANOVA followed by Tukey’s HSD test and are represented as different letters with a
p<0.05.
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Figure 10: Daily supplementation of human recombinant galectin-3 exhibits no effect
on granulocytic differentiation of HL-60 cells.
HL-60 cells were supplemented daily with 1000 ng/mL of galectin-3, with half the cells
being treated with 1 µM ATRA for 72 h. (A) Nuclear morphology of control and galectin3 treated cells were visualized by DAPI staining with the scale bar representing 20 µm.
The differentiation index was determined as the percentage of nuclei demonstrating multilobular granulocyte-like shape based on galectin-3 (340 – 400 cells counted) (B) and
galectin-3 + ATRA (230 – 340 cells counted) treatments (C). (D) Granulocyte specific
gene NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an
internal control for galectin-3 and galectin-3+ATRA treatments. (E) O-GlcNAcylation was
assessed by immunodot blot using the RL2 antibody of galectin-3 ± ATRA treatments.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and Two-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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percentage of segmented nuclei (p<0.0001), upregulation in NCF1 expression (p<0.01),
and a decrease in global O-GlcNAcylation (p<0.05) relative to untreated cells (Figure 9AF).
Cells daily supplemented with 1000 ng/mL of galectin-3 + ATRA exhibited no significant
change in the percentage of segmented nuclei (86.4 ± 4.1%) relative to ATRA treated cells
(86.1 ± 3.6%) (Figure 10A, C). Furthermore, there was no significant change in the
expression of NCF1 observed with galectin-3 + ATRA treatment (25.2-fold) relative to
ATRA treated cells (33.7-fold) (Figure 10D). Additionally, there was no significant
change in global O-GlcNAcylation levels observed with galectin-3 + ATRA treated cells
(72.8%) relative to ATRA treated cells (67.4%) (Figure 10E). The ATRA treatment for
the daily supplementation with galectin-3 + ATRA demonstrated an increase in the
percentage of segmented nuclei (p<0.0001), upregulation in NCF1 expression (p<0.05),
and a decrease in global O-GlcNAcylation (p<0.01) relative to untreated cells (Figure
10A-E).
GB1107 is a specific allosteric inhibitor of galectin-3 that was used to investigate the
effects of galectin-3 inhibition on granulocytic differentiation. HL-60 cells were treated
with 2 µM GB1107 daily over 72 hours. GB1107 treated cells exhibited a significant
increase in the percentage of segmented nuclei (5.0 ± 0.6%) relative to untreated cells (2.3
± 0.7%, p<0.01) (Figure 11A-B). Furthermore, GB1107 treated cells demonstrated a
significant upregulation in NCF1 (2.0-fold) relative to untreated cells (p<0.05) (Figure
11D). Global O-GlcNAcylation levels also significantly decreased in GB1107 treated cells
(38.4%) relative to untreated cells (p<0.01) (Figure 11F-G).
The galectin-3 inhibitor GB1107 was also used in a combination treatment with ATRA to
further assess the effect galectin-3 has on granulocytic differentiation of HL-60 cells. HL60 cells were treated with 1 µM ATRA and daily supplemented with 2 µM GB1107 for 72
hours. Nuclear morphology exhibited no significant change in the percentage of segmented
nuclei of GB1107 + ATRA treated cells (69.8 ± 4.3%) relative to ATRA treated cells (76.5
± 2.8%) (Figure 11A, C). Furthermore, there was no significant change in NCF1
expression of GB1107 + ATRA treated cells (114.7-fold) relative to ATRA treated cells
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Figure 11: Allosteric inhibition of galectin-3 with GB1107 induces granulocytic
differentiation of HL-60 cells.
HL-60 cells were supplemented daily with 2 µM GB1107, with half the cells being treated
with 1 µM ATRA for 72 h. (A) Nuclear morphology of control and GB1107 treated cells
were visualized by DAPI staining with the scale bar representing 20 µm.

The

differentiation index was determined as the percentage of nuclei demonstrating multilobular granulocyte-like shape based on GB1107 (150 – 200 cells counted) (B) and
GB1107 + ATRA (130 – 230 cells counted) treatments (C). (D) Granulocyte specific genes
NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an
internal control for GB1107 and GB1107 + ATRA treatments. (E) O-GlcNAcylation was
assessed by immunodot blot using the RL2 antibody GB1107 treatments (G), and GB1107
+ ATRA treatments (H). Data are presented as mean ± SD, n=3-4. Significant differences
were determined using unpaired Student’s t test and Two-way ANOVA followed by
Tukey’s HSD test and are represented as different letters with a p<0.05.
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(75.7-fold) (Figure 11E). Additionally, there was no significant change observed in global
O-GlcNAcylation levels of GB1107 + ATRA treated cells (44.8%) relative to ATRA
treated cells (34.2%) (Figure 11F, H). The ATRA treatment with GB1107 + ATRA
demonstrated an increase in the percentage of segmented nuclei (p<0.0001), upregulation
of NCF1 expression (p<0.0001), and a decrease in global O-GlcNAcylation (p<0.05)
relative to untreated cells (Figure 11A-H).

3.1.4

The effects of tandem-repeat type recombinant galectin-8
and galectin-9 on differentiation of HL-60 cells

Galectin-8 is another galectin that exhibits constant expression patterns during
differentiation in HL-60 cells (Abedin et al., 2003; Timoshenko et al., 2016; Vinnai et al.,
2017). To examine the effects of galectin-8 on HL-60 cell granulocytic differentiation,
dose-dependent treatments of human recombinant galectin-8 at 10, 100 or 1000 ng/mL
were conducted over 72 hours. Nuclear morphology showed that cell treatments at 1000
ng/mL had a significant increase in the percentage of segmented nuclei (9.1 ± 0.3%,
p<0.05) relative to untreated cells (3.8 ± 2.8%), whereas cells treated with 10 ng/mL (4.7
± 0.7%) or 100 ng/mL (6.5 ± 1.5%) exhibited no significant changes in the segmentation
of nuclei (Figure 12A-B).

Furthermore, 1000 ng/mL of galectin-8 demonstrated a

significant upregulation in NCF1 expression (4.3-fold, p<0.001) relative to untreated cells,
while 10 ng/mL (1.3-fold) and 100 ng/mL (1.0-fold) demonstrated no significant changes
in NCF1 expression (Figure 12D). However, there was no significant change observed at
1000 ng/mL of galectin-8 treated cells on global O-GlcNAcylation levels (19.5%) relative
to untreated cells (Figure 12F).
To further understand the effects of 1000 ng/mL of recombinant galectin-8 on HL-60 cell
differentiation, daily supplementation of 1000 ng/mL of galectin-8 was conducted over 72
hours.

Daily supplemented galectin-8 cells exhibited a significant increase in the

percentage of segmented nuclei (6.9 ± 1.5%) relative to untreated cells (2.3 ± 0.6%,
p<0.01) (Figure 13A-B). However, there were no significant changes observed in the
expression of NCF1 (5.3-fold) and global O-GlcNAcylation (14.7% increase) relative to
untreated cells (Figure 13D-E).
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Figure 12: Human recombinant galectin-8 induces granulocytic differentiation of
HL-60 cells.
HL-60 cells were treated with 10, 100, or 1000 ng/mL of galectin-8, with half the cells also
being treated with 1 µM ATRA to induce differentiation for 72 h. (A) Nuclear morphology
of control and galectin-8 treated cells were visualized by DAPI staining with the scale bar
representing 20 µM. The differentiation index was determined as the percentage of nuclei
demonstrating multi-lobular granulocyte-like shape based on galectin-8 (220 – 540 cells
counted) (B) and galectin-8+ATRA (230 – 440 cells counted) treatments (C). Granulocyte
specific gene NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using
ACTB as an internal control for galectin-8 (D) and galectin-8 + ATRA treatments (E). (F)
O-GlcNAcylation was assessed by immunodot blot using the RL2 antibody when HL-60
cells were treated with 1000 ng/mL of galectin-8 ± ATRA. Data are presented as mean ±
SD, n=3-4. Significant differences were determined using One-way ANOVA and Twoway ANOVA followed by Tukey’s HSD test and are represented as different letters with a
p<0.05.
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Figure 13: Daily supplementation effects of human recombinant galectin-8 on
granulocytic differentiation of HL-60 cells.
HL-60 cells were supplemented daily with 1000 ng/mL of galectin-8, with half the cells
being treated with 1 µM ATRA for 72 h. (A) Nuclear morphology of control and galectin8 treated cells were visualized by DAPI staining with the scale bar representing 20 µm.
The differentiation index was determined as the percentage of nuclei demonstrating multilobular granulocyte-like shape based on galectin-8 (170 – 280 cells counted) (B) and
galectin-8 + ATRA (210-290 cells counted) treatments (C). (D) Granulocyte specific gene
NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an
internal control for galectin-8 and galectin-8 + ATRA treatments. (E) O-GlcNAcylation
was assessed by immunodot blot using the RL2 antibody of galectin-8 ± ATRA treatments.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and Two-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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To get a more in-depth look at the effect of galectin-8 on the granulitic differentiation of
HL-60 cells, combination treatments with ATRA were conducted. HL-60 cells were
treated with 1 µM ATRA and treated with dose-dependent concentrations (10, 100 or 1000
ng/mL) or supplemented daily with recombinant galectin-8 (1000 ng/mL) for 72 hours.
Nuclear morphology of dose-dependent cell treatments of galectin-8 + ATRA exhibited a
significant decrease in the percentage of segmented nuclei at 1000 ng/mL (77.7 ± 3.6%,
p<0.05) relative to ATRA treated cells (86.0 ± 1.5%), whereas 10 ng/mL (82.7 ± 2.9%)
and 100 ng/mL (82.3 ± 2.9%) cell treatments demonstrated no significant changes in the
percentage of segmented nuclei (Figure 12A, C). Furthermore, there were no significant
changes in NCF1 expression at all galectin-8 + ATRA concentrations (314.6-fold, 174.2fold, and 256.5-fold, respectively) relative to ATRA treated cells (154.2-fold) (Figure
12E).

Additionally, there was no significant change observed in the global O-

GlcNAcylation levels when treated with 1000 ng/ml of galectin-8 + ATRA (47.4%)
relative to ATRA treated cells (39.4%) (Figure 12F). The ATRA treatment for the dose
dependent effects with galectin-8 + ATRA demonstrated an increase in the percentage of
segmented nuclei (p<0.0001), upregulation in NCF1 expression (p<0.001), and decrease
in global O-GlcNAcylation (p<0.05) relative to untreated cells (Figure 12A-F).
Daily supplementation of 1000 ng/mL of galectin-8 + ATRA exhibited a significant
decrease in the percentage of segmented nuclei (67.0 ± 1.5%, p<0.01) relative to ATRA
treated cells (82.4 ± 0.6%) (Figure 13A, C). Furthermore, there was no significant change
in the expression of NCF1 of galectin-8 + ATRA treated cells (85.2-fold) relative to ATRA
treated cells (62.3-fold) (Figure 13D). Global O-GlcNAcylation levels demonstrated no
significant change with galectin-8+ATRA treated cells (68.3%) relative to ATRA treated
cells (59.3%) (Figure 13E). The ATRA treatment for the daily supplementation with
galectin-8 + ATRA demonstrated an increase in the percentage of segmented nuclei
(p<0.0001), upregulation of NCF1 expression (p<0.05), and decrease in global OGlcNAcylation (p<0.01) (Figure 13A-E).
Previous reports have indicated that galectin-9 exhibits constant gene expression during
DMSO-induced differentiation of HL-60 cells (Vinnai et al., 2017; Abedin et al., 2003).
To see how galectin-9 is involved with the granulocytic differentiation of HL-60 cells, the
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dose dependent effects of human recombinant galectin-9 at 10, 100, or 1000 ng/mL were
investigated over the 72 hours. Nuclear morphology showed no significant changes in the
percentage of segmented nuclei (5.3 ± 0.4, 5.2 ± 1.7, and 11.5 ± 5.2%, respectively) relative
to untreated cells (5.1 ± 2.0%) (Figure 14A-B). Furthermore, treatment with 1000 ng/mL
galectin-9 resulted in a significant upregulation in NCF1 expression (11.0-fold, p<0.05)
relative to untreated cells, while 10 ng/mL (0.9-fold) and 100 ng/mL (0.8-fold)
demonstrated no significant changes in NCF1 expression (Figure 14D). Additionally, there
was no significant change observed in global O-GlcNAcylation of cells treated with 1000
ng/mL of galectin-9 (6.6% increase) relative to untreated cells (Figure 14F).
Daily supplementation of recombinant galectin-9 at 1000 ng/mL was also conducted over
72 hours. Nuclear morphology exhibited no significant change in the percentage of
segmented nuclei of galectin-9 treated cells (2.8 ± 1.2%) relative to untreated cells (1.1 ±
0.5%) (Figure 15A-B).

Furthermore, there were no significant changes in NCF1

expression of galectin-9 treated cells (4.4-fold) or in global O-GlcNAcylation (3.9%)
relative to untreated cells (Figure 15D-E).
To understand how galectin-9 is involved in ATRA-induced differentiation of HL-60 cells,
combination treatments were also conducted. Cells were treated with 1 µM ATRA and
dose-dependent effect concentrations (10, 100, or 1000 ng/mL) or daily supplementation
with recombinant galectin-9 (1000 ng/mL) for 72 hours. The dose-dependent treatments
of galectin-9 + ATRA exhibited no significant change in the percentage of segmented
nuclei (86.9 ± 7.5, 82.5 ± 3.9, and 80.1 ± 6.3%, respectively) relative to ATRA treated cells
(91.1 ± 3.5%) (Figure 14A, C). Furthermore, there was no significant change observed in
the expression of NCF1 galectin-9 + ATRA treated cells (163.7-fold, 234.9-fold, and
214.0-fold, respectively) relative to ATRA treated cells (142.2-fold) (Figure 14E).
Additionally, global O-GlcNAcylation levels demonstrated no significant change upon
treatment with galectin-9 + ATRA (40.1%) relative to ATRA treated cells (39.4%) (Figure
14F).

The ATRA treatment for the dose dependent effects with galectin-9 + ATRA

demonstrated an increase in the percentage of segmented nuclei (p<0.0001), upregulation
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Figure 14: Dose-dependent effects of human recombinant galectin-9 on granulocytic
differentiation of HL-60 cells.
HL-60 cells were treated with 10, 100, or 1000 ng/mL of galectin-9, with half the cells also
being treated with 1 µM ATRA to induce differentiation for 72 h. (A) Nuclear morphology
of control and galectin-9 treated cells were visualized by DAPI staining with the scale bar
representing 20 µm. The differentiation index was determined as the percentage of nuclei
demonstrating multi-lobular granulocyte-like shape based on galectin-9 (100 – 380 cells
counted) (B) and galectin-9 + ATRA (200 – 370 cells counted) treatments (C).
Granulocyte specific gene NCF1 was quantified by RT-qPCR with the Livak method (2∆∆Ct

) using ACTB as an internal control for galectin-9 (D) and galectin-9 + ATRA

treatments (E). (F) O-GlcNAcylation was assessed by immunodot blot using the RL2
antibody when HL-60 cells were treated with 1000 ng/mL galectin-9 ± ATRA. Data are
presented as mean ± SD, n=3-4. Significant differences were determined using One-way
ANOVA and Two-way ANOVA followed by Tukey’s HSD test and are represented as
different letters with a p<0.05.
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Figure 15: Daily supplementation effects of human recombinant galectin-9 on
granulocytic differentiation of HL-60 cells.
HL-60 cells were supplemented daily with 1000 ng/mL of galectin-9, with half the cells
being treated with 1 µM ATRA for 72 h. (A) Nuclear morphology of control and galectin9 treated cells were visualized by DAPI staining with the scale bar representing 20 µm.
The differentiation index was determined as the percentage of nuclei demonstrating multilobular granulocyte-like shape based on galectin-9 (140 – 290 cells counted) (B) and
galectin-9 + ATRA (190 – 350 cells counted) treatments (C). (D) Granulocyte specific
genes NCF1 was quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an
internal control for galectin-9 and galectin-9+ATRA treatments. (E) O-GlcNAcylation was
assessed by immunodot blot using the RL2 antibody of galectin-9 ± ATRA treatments.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and Two-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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of NCF1 expression (p<0.01) and decrease in global O-GlcNAcylation (p<0.05) relative
to untreated cells (Figure 14A-F).
When examining the effects of daily supplementation with 1000 ng/mL galectin-9 +
ATRA, there was no significant change in the percentage of segmented nuclei (83.2 ±
8.6%) relative to ATRA treated cells (81.8 ± 6.4%) (Figure 15A, C). Furthermore, daily
supplementation of galectin-9 + ATRA displayed a significant upregulation in the
expression of NCF1 (121.5-fold, p<0.01) relative to ATRA treated cells (60.9-fold)
(Figure 15D). However, there was no significant change observed in the levels of OGlcNAcylation of galectin-9 + ATRA treated cells (29.9%) relative to ATRA treated cells
(64.9%) (Figure 15E). The ATRA treatment for the daily supplementation with galectin9 + ATRA demonstrated an increase in the percentage of segmented nuclei (p<0.0001),
upregulation of NCF1 expression (p<0.001), and decrease in global O-GlcNAcylation
(p<0.01) relative to untreated cells (Figure 15A-E).

3.2 HL-60 cells exhibit resistance to galectin-induced
apoptosis
3.2.1

Brefeldin-A treatment of HL-60 cells results in hallmarks of
apoptosis not observed with all-trans retinoic acid

HL-60 cells can undergo apoptosis when treated with various agents. Brefeldin A (BFA)
is a lactone produced by fungi that inhibits protein transport between the endoplasmic
reticulum and Golgi Apparatus by preventing association of COP-I coat vesicles (Shao et
al., 1996). Previous research with HL-60 cells has shown that 0.5-10 µM BFA induced
high levels of apoptosis (Andersen et al., 2016). There are several factors that change
during cellular apoptosis including the condensation of DNA and changes in gene
expression. In this study, the degree of apoptosis induced by BFA in HL-60 cells was
assessed. HL-60 cells were treated with 0.01,0.1, 1, or 10 µM BFA for 24 hours prior to
nuclear imaging and gene expression analysis.
Untreated HL-60 cells exhibited circular morphology whereas BFA treated HL-60 cells
exhibited condensed morphology for apoptotic cells. HL-60 cells treated with 0.01 µM
BFA exhibited no significant changes in the percentage of apoptotic cells (2.2 ± 0.1%)
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relative to untreated cells (0.6 ± 0.5%). However, 0.1 µM (42.7 ± 14.7%, p<0.001), 1 µM
(49.3 ± 7.0%, p<0.0001), and 10 µM (56.9 ± 7.7%, p<0.0001) exhibited an increase in the
percentage of apoptotic cells (Figure 16A-B). CHOP and BAX are two proteins that
demonstrate increased expression during apoptosis (Choi et al. 2010; Namba et al., 2013).
RT-qPCR was performed to assess the changes in expression of CHOP and BAX of cells
treated with 1 µM BFA.

BFA treated cells demonstrated 141.3-fold (p<0.0001)

upregulation in CHOP and 8.2-fold (p<0.01) upregulation in BAX (Figure 16C-D).
Previous research with ATRA has shown induced apoptosis at 1 µM ATRA (Veselská et
al., 2003).

HL-60 cells were treated with 1 µM ATRA for 72 hours and nuclear

condensation and associated gene expression changes were assessed. ATRA treated HL60 cells demonstrated no significant changes in apoptotic cells (2.9 ± 1.3%) relative to
untreated cells (0.5 ± 0.9%) (Figure 17A). Additionally, there were no changes observed
in the expression of both CHOP (1.5-fold) and BAX (0.9-fold) (Figure 17B-C).

3.2.2

Effect of recombinant galectins on HL-60 cell apoptosis

Previous research with galectins has shown induced apoptosis in immune cells. However,
little is known with respect to galectin induced apoptosis in HL-60 cells. In this study, HL60 cells were treated with dose dependent concentrations (10, 100, or 1000 ng/mL) or
supplemented daily with human recombinant galectin -1 (1000 ng/mL) for 72 hours. HL60 cells treated with recombinant galectin-1 demonstrated no change in the percentage of
apoptotic cells at 10 ng/mL (0.2 ± 0.4%), with significant increases observed with 100
ng/mL (1.4 ± 0.3%, p<0.05) and 1000 ng/mL (1.0 ± 0.4%, p<0.05) relative to untreated
cells (0.4 ± 0.3%) (Figure 18A). Furthermore, HL-60 cells treated with 1000 ng/mL of
galectin-1 demonstrated no significant changes in CHOP (1.1-fold) or BAX (3.0-fold)
expression relative to untreated cells (Figure 18B-C). Additionally, daily supplemented
HL-60 cells with 1000 ng/mL of galectin-1 exhibited no significant change in the
percentage of apoptotic cells (1.3 ± 0.6%) relative to untreated cells (1.2 ± 0.4%) (Figure
18D). Daily supplemented HL-60 cells also demonstrated no significant changes in CHOP
(1.2-fold) or BAX (1.9-fold) expression relative to untreated cells (Figure 18E-F).
To provide further insights into galectins and apoptosis in HL-60 cells, treatments with
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Figure 16: Brefeldin-A induced apoptosis of HL-60 cells.
HL-60 cells were treated with either 0.01, 0.1, 1, or 10 µM BFA for 24 hr. (A) Nuclear
morphology of untreated and BFA treated cells were visualized by DAPI staining with the
scale bar representing 20 µm. Non-apoptotic cells demonstrated circular nuclei (white
arrow) and apoptotic cells demonstrated condensed nuclei (red arrow). (B) The apoptotic
index was determined as the percentage of nuclei demonstrating DNA condensation based
on BFA treatment (220 – 480 cells counted). Changes in the expression of genetic markers
of apoptosis CHOP (C) and BAX (D) were quantified by RT-qPCR with the Livak method
(2-∆∆Ct) using ACTB as an internal control. Data are presented as means ± SD, n=3.
Statistical differences were determined using the unpair Student’s t test and One-way
ANOVA followed by Tukey’s HSD test and are represented as different letters with a
p<0.05.
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Figure 17: ATRA did not induce apoptosis in HL-60 cells.
HL-60 cells were treated with 1 µM ATRA to induce granulocytic differentiation for 72 h.
(A) The apoptotic index was determined as the percentage of nuclei demonstrating DNA
condensation (100 – 400 cells counted). Apoptotic gene markers CHOP (B) and BAX (C)
were quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an internal
control. Data are presented as the mean ± SD, n=3.
determined using unpaired Student’s t-test.

Significant differences were
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Figure 18: HL-60 cells exhibit resistance to galectin-1 induced apoptosis.
HL-60 cells were treated with dose dependent concentrations of 10, 100, or 1000 ng/mL or
daily supplemented with 1000 ng/mL recombinant galectin-1 72 hr. The apoptotic index
was determined as the percentage of nuclei demonstrating DNA condensation of dosedependent (130 – 205 cells counted) (A) and daily supplementation (150 – 300 cells
counted) (D).

Apoptotic gene markers CHOP for dose dependent (B) and daily

supplementation (E); and BAX for dose dependent (C) and daily supplementation (F) were
quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an internal control.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and One-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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galectin-3 were also assessed. Dose dependent concentrations (10, 100, or 1000 ng/mL)
of galectin-3 over 72 hours exhibited no significant changes in the percentage of apoptotic
cells (0.5 ± 0.3, 0.8 ± 0.3, 1.1 ± 0.4%, respectively) relative to untreated cells (0.6 ± 0.6%)
(Figure 19A).

Furthermore, HL-60 cells treated with 1000 ng/mL of galectin-3

demonstrated no significant changes in CHOP (1.0-fold) or BAX (0.6-fold) gene
expressions relative to untreated cells (Figure 19B-C).

HL-60 cells were also

supplemented daily with 1000 ng/mL of galectin-3 over 72 hours. Daily supplemented
cells exhibited no significant change in the percentage of apoptotic cells (0.6 ± 0.1%)
relative to untreated cells (0.3 ± 0.4%) (Figure 19D). Furthermore, daily supplemented
cells demonstrated no significant changes in CHOP (0.6-fold) or BAX (0.8-fold) gene
expressions relative to untreated cells (Figure 19E-F).
HL-60 cells were also treated with dose dependent concentrations (10, 100, or 1000 ng/mL)
or daily supplemented with human recombinant galectin-8 (1000 ng/mL) over 72 hours.
HL-60 cells treated with 1000 ng/mL of galectin-8 exhibited a significant increase in the
percentage of apoptotic cells (3.1 ± 0.7%, p<0.01) that was not observed with 10 ng/mL
(1.0 ± 0.6%) or 100 ng/mL (2.0 ± 0.6%) relative to untreated cells (0.7 ± 0.3%) (Figure
20A). However, HL-60 cells treated with 1000 ng/mL of galectin-8 demonstrated no
significant changes in CHOP (1.4-fold) or BAX (1.1-fold) gene expressions relative to
untreated cells (Figure 20B-C). Additionally, HL-60 cells daily supplemented with 1000
ng/mL of galectin-8 exhibited a significant increase in the percentage of apoptotic cells
(6.1 ± 1.3%, p<0.01) relative to untreated cells (1.3 ± 0.8%) (Figure 20D). Furthermore,
HL-60 cells daily supplemented with galectin-8 demonstrated no significant changes in
CHOP (1.2-fold) or BAX (1.2-fold) gene expressions relative to untreated cells (Figure
20E-F).
Finally, the effects of galectin-9 on HL-60 cells apoptosis were also assessed. HL-60 cells
were treated with the dose dependent concentrations (10, 100 or 1000 ng/mL) or daily
supplemented with human recombinant galectin-9 (1000 ng/mL) for 72 hours. Dose
dependent concentrations exhibited no significant changes in the percentage of apoptotic
cells (0.5 ± 0.4, 0.6 ± 1.1, 1.4 ± 2.3%, respectively) relative to untreated cells (0.5 ± 0.2%)
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Figure 19: HL-60 cells exhibit resistance to galectin-3 induced apoptosis.
HL-60 cells were treated with dose dependent concentrations of 10, 100, or 1000 ng/mL or
daily supplemented with 1000 ng/mL recombinant galectin-3 72 hr. The apoptotic index
was determined as the percentage of nuclei demonstrating DNA condensation of dosedependent (170 – 360 cells counted) (A) and daily supplementation (340 – 400 cells
counted) (D).

Apoptotic gene markers CHOP for dose dependent (B) and daily

supplementation (E); and BAX for dose dependent (C) and daily supplementation (F) were
quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an internal control.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and One-way ANOVA followed by Tukey’s HSD test.
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Figure 20: HL-60 cells exhibit resistance to galectin-8 induced apoptosis.
HL-60 cells were treated with dose dependent concentrations of 10, 100, or 1000 ng/mL or
daily supplemented with 1000 ng/mL recombinant galectin-8 72 hr. The apoptotic index
was determined as the percentage of nuclei demonstrating DNA condensation of dosedependent (220 – 540 cells counted) (A) and daily supplementation (170 – 280 cells
counted) (D).

Apoptotic gene markers CHOP for dose dependent (B) and daily

supplementation (E); and BAX for dose dependent (C) and daily supplementation (F) were
quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an internal control.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and One-way ANOVA followed by Tukey’s HSD test and are
represented as different letters with a p<0.05.
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(Figure 21A).

Furthermore, HL-60 cells treated with 1000 ng/mL of galectin-9

demonstrated no significant changes in CHOP (1.3-fold) or BAX (1.3-fold) gene
expressions relative to untreated cells (Figure 21B-C). Additionally, HL-60 cells daily
supplemented with 1000 ng/mL of galectin-9 exhibited no significant changes in the
percentage of apoptotic cells (2.8 ± 1.2%) relative to untreated cells (1.1 ± 0.5%) (Figure
21D). HL-60 cells daily supplemented with galectin-9 also demonstrated no significant
changes in CHOP (0.5-fold) or BAX (0.9-fold) gene expressions relative to untreated cells
(Figure 21E-F).

3.3 In silico analysis of the relationship between galectins
and cell differentiation biomarkers in acute myeloid
leukemia and FAB subtypes
There are various galectins expressed in bone marrow and AML cells. Analysis of TCGA
data indicated gene expression of galectin 1, 3, 4, 7, 8, 9, 10, and 12 in both bone marrow
and AML cohorts. Differential expression analysis revealed no significant changes in
LGALS expression, except for LGALS9 demonstrating a significant upregulation (1.1-fold,
p<0.05) relative to bone marrow cohorts (Table 1) (Figure 22A). Additionally, O-GlcNAc
cycle enzymes, granulocytic differentiation markers, and most stemness markers
demonstrated no significant changes in gene expression in AML relative to bone marrow
cohorts. Nanog homeobox (NANOG) was the only stemness marker revealed to be
significantly downregulated in AML cohorts (0.9-fold, p<0.0001) relative to bone marrow
control (Table 1) (Figure 22B-C).
To provide a further understanding of galectin gene expression in AML, patient data were
separated into individual FAB subtype classification including M0-M5. Differential
expression analysis of the FAB subtypes revealed that there were no significant changes in
galectin gene expression specifically in the M0-M2 subtype, while the M3-M5 subtypes
demonstrated significant changes in galectin gene expression relative to bone marrow
cohorts. The M3 subtype exhibited the largest total of significant changes in galectin gene
expression. LGALS1 in the M4 (2.1-fold, p<0.001) and M5 (4.2-fold, p<0.0001) subtypes,
and LGALS3 in the M4 (2.5-fold, p<0.001) and M5 (4.5-fold, p<0.01) subtypes
demonstrated a significant upregulation in gene expression relative to bone marrow
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Figure 21: HL-60 cells exhibit resistance to galectin-9 induced apoptosis.
HL-60 cells were treated with dose dependent concentrations of 10, 100, or 1000 ng/mL or
daily supplemented with 1000 ng/mL recombinant galectin-9 72 hr. The apoptotic index
was determined as the percentage of nuclei demonstrating DNA condensation of dosedependent (100 – 380 cells counted) (A) and daily supplementation (140 – 290 cells
counted) (D).

Apoptotic gene markers CHOP for dose dependent (B) and daily

supplementation (E); and BAX for dose dependent (C) and daily supplementation (F) were
quantified by RT-qPCR with the Livak method (2-∆∆Ct) using ACTB as an internal control.
Data are presented as mean ± SD, n=3-4. Significant differences were determined using
unpaired Student’s t test and One-way ANOVA followed by Tukey’s HSD test.
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Figure 22: Differential gene expression analysis of TCGA AML cohorts .
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio prior to statistical analysis. Various galectin genes
(LGALS) (A), O-GlcNAc related enzymes (OGA, OGT, GFAT1) and granulocyte
differentiation marker genes (NCF1/2, CYBA/N, MPO) (B), as well as stemness marker
genes (OCT4, NANOG, FOX2, C-MYC, KLF4, CD34) (C) were log2 transformed to assess
expression. Data is presented as violin plots, n=70-126. Statistical significance was
determined using the nonparametric Mann Whitney test. *p≤0.05, ****p≤0.0001.
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Table 1: Subtype-specific gene expression patterns in TCGA cohort of AML.
Gene
AML

M0

M1

LGALS1

0.0414

-0.668

-0.215

LGALS3

0.0102

-0.845

LGALS4

0.107

LGALS7

Cell Type
M2

M3

M4

M5

-0.829

-0.583

1.0458***

2.0713****

-0.903

-0.698

0.447

1.303***

2.170**

0.184

-0.0215

-0.0323

1.0852*

-0.314

0.4814

-0.972

-0.578

-0.767

-1.292

-1.568

-1.407

0.0228

LGALS8

-0.0137

-0.0548

-0.0507

0.0513

-0.298**

0.0769

0.0833

LGALS9

0.0692*

-0.157

0.343

0.232

-1.938***

0.215

0.713**

CLC

0.0119

-0.713

-0.123

0.634

0.777

0.649

-1.966

LGALS12

-0.0292

-1.345

-0.907

-0.786

3.991****

-0.0059

1.448

Galectins

O-GlcNAc related cycle enzymes
OGA

-0.0195

0.241

0.0146

0.0177

-0.033

0.00096

-0.428*

OGT

-0.0132

0.169

0.0741

-0.0047

0.393

-0.121

-0.599*

GFAT1

-0.055

-0.0472

-0.170

-0.0643

0.312*

0.0555

-0.236

Granulocyte differentiation markers
NCF1

0.0353

-1.497*

-0.442

-0.591

-1.816*

1.998***

2.374**

NCF2

0.00597

-0.834

-0.606

-0.477

-1.619

1.744****

1.961***

CYBA

0.0538

-0.878*

0.0362

-0.200

0.178

0.274

0.972***

CYBB

0.02075

-0.971

-1.0602

-0.637

0.426

2.0047****

1.548

MPO

0.171

-3.890**

0.737

1.041

4.294****

-0.414

-2.217

Stemness markers
OCT4

0.00818

-0.303

0.105

-0.0749

-0.219

0.0208

0.374

NANOG

-0.0791****

-0.188

-0.338**

-0.153*

-0.284

0.185

0.593

FOX2

-0.0355

0.976

0.112

-0.346

-0.542

-0.489

0.509

C-MYC

0.0142

-0.478

0.345

0.536

-0.0301

-0.341

-0.898

KLF4

0.0396

-1.054

-0.648

-0.937

-0.982

1.889****

2.739****

CD34

0.0876

3.391***

-0.302

2.612****

-3.407

0.139

-4.056*

-0.104

0.127

0.133

0.186

-0.286

-0.0475

Housekeeping gene
HMBS

0.0197

Notes: GTEx bone marrow and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and log2 transformed in Microsoft excel prior to
statistical analysis. The log2 fold change was calculated and compared to bone marrow
control for all AML cohorts (n=126) and molecular subtypes including M0 (n=12), M1
(n=36), M2 (n=29), M3 (n=12), M4 (n=22), and M5 (n=14). Statistical significance was
determined using the nonparametric Kruskal-Wallis test followed by Dunn’s multiple
comparisons. *p≤0.05, **p ≤0.01, ***p ≤0.001, ****p≤0.0001.
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cohorts. Additionally, LGALS8 (0.3-fold, p<0.001) and LGALS9 (0.3-fold, p<0.001)
both demonstrated a significant downregulation in the M3 subtype relative to bone
marrow cohorts. LGALS4 (2.1-fold, p<0.05) and LGALS12 both demonstrated a
significant upregulation in the M3 subtype relative to bone marrow cohorts.
Furthermore, a LGALS12/LGALS9 ratio was specifically upregulated in the M3 FAB
subtype that was not seen in other FAB subtypes or in bone marrow cohorts (p<0.0001).
However, when looking at LGALS7 and CLC FAB subtype expression profiles, there
were no significant changes in any of the FAB subtypes relative to bone marrow cohorts
(Table 1) (Figure 23).
To further evaluate the expression patterns of galectins in AML, differential expression
analysis of O-GlcNAc cycle enzymes, granulocyte differentiation markers and stemness
markers expression profiles were analyzed for FAB subtypes M0-M5.

There were

significant changes observed with downregulation of O-GlcNAc cycle enzymes OGA (0.7fold, p<0.05) and OGT (0.7-fold, p<0.05) in the M5 subtype, and a significant upregulation
of GFAT1 (1.2-fold, p<0.05) in the M3 subtype relative to bone marrow cohorts (Table 1)
(Figure S2). Additionally, an OGT/GFAT1 ratio was significantly downregulated in the
M0 FAB subtype that was not observed in other FAB subtypes or bone marrow cohorts
(p<0.0001) (Figure S2). Furthermore, there were significant upregulations in the gene
expression of granulocyte differentiation markers NCF1 in the M4 (4.0-fold, p<0.001) and
M5 (5.2-fold, p<0.01) subtypes, and NCF2 in the M4 (3.4-fold, p<0.0001) and M5 (3.9fold, p<0.001) subtypes relative to bone marrow cells (Table 1) (Figure 23). Other
granulocytic differentiation markers and stemness markers including CYBB, CYBA, MPO,
KLF4, and CD34 demonstrated significant changes in the M3-M5 FAB subtypes, while
NCF1, NCF2, MPO, NANOG and CD34 demonstrated significant changes in expression
in the M0-M2 FAB subtypes (Table 1) (Figure S3).
The relationship between galectin genes and the other markers of interest in this study have
yet to be investigated. Therefore, pairwise correlations were performed between the
various genes of interest of both AML and bone marrow cohorts. Correlation strengths of
genes in bone marrow and AML cohorts are represented as heatmaps (Figure 24A). There
were significant changes in the pairwise correlations of many genes when comparing
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Figure 23: Differential expression analysis of TCGA AML subtypes reveals changes
in LGALS gene expression in M3-M5 subtypes.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and log2 transformed in Microsoft excel prior to
statistical analysis. The subtypes investigated include M0 (n=12), M1 (n=36), M2 (n=29),
M3 (n=12), M4 (n=22), and M5 (n=14) and compared to BM control (n=70). Various
galectin genes including LGALS1, LGALS3, LGALS4, LGALS7, LGALS8, LGALS9, CLC,
LGALS12, and a ratio of LGALS12/LGALS9 were examined. Granulocyte differentiation
markers NCF1 and NCF2 were also examined. Data is represented as violin plots.
Statistical significance was determined using the nonparametric Kruskal-Wallis test
followed by Dunn’s multiple comparisons and are represented as different letters with a
p<0.05.
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Figure 24: Spearman's correlation of bone marrow and AML cohorts reveals global
changes in glycobiological associations in AML patients.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and the data log2 transformed prior to statistical analysis.
(A) Heatmaps for Spearman’s correlation (ρ) of both BM (n=70) and AML (n=126)
samples. (B) Changes in correlation between BM to AML were evaluated in R studios
using the “cocor” package with blue indicating a change to positive correlation, red
indicating a change to negative correlation, yellow indicating a change in correlation
strength, and green indicating a loss in correlation in AML cohorts. *p≤0.05, **p ≤0.01,
***p ≤0.001, ****p≤0.0001.
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between bone marrow and AML cohorts (Figure 24B). When looking particularly at the
correlations between galectin genes, there were significant changes observed with a gain
of positive association with LGALS1 and LGALS3 (p<0.0001), with LGALS3 and
LGALS12 (p<0.001), with LGALS8 and LGALS9 (p<0.001), and a loss of association with
LGALS1 and CLC relative to bone marrow cohorts (Figures 24, 25). Additionally, there
were significant changes in the correlation of galectin genes to granulocyte differentiation
markers. More specifically, there was a significant correlation switch observed of a gain
of positive association of LGALS1 with NCF1 (p<0.001) and NCF2 (p<0.0001), LGALS3
with NCF1 (p<0.0001) and NCF2 (p<0.0001), and LGALS8 with NCF1 (p<0.0001) and
NCF2 (p<0.0001) with reference to bone marrow cohort (Figures 24, 26).
To conclude the analysis of galectin gene expression in AML, patient survival was
examined relative to galectin median gene expression of all AML cohorts and the M0-M5
FAB subtypes. Examining all AML cohorts revealed that an above median expression of
LGALS1 was significantly indicated of poor prognosis (p<0.0001) (Figure 27A).
However, there were no other significant indications of prognosis observed for the
expression of other galectin genes (Figure S5). When examining the M1-M5 FAB
subtypes, there were no significant indications of prognosis observed for all galectin genes
(Figure S10-15).

However, when looking at the M0 FAB subtype, above median

expression of LGALS1 (p<0.01), LGALS4 (p<0.05), and CLC (p<0.05) were significantly
indicative of poor prognosis (Figure 27B-D).
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Figure 25: Pairwise scatter plots of Spearman's correlation indicates a change in
LGALS gene expression regulation in AML patients.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and the data log2 transformed prior to statistical
analysis. Correlations and regression line analysis between LGALS1 and LGALS3,
LGALS1 and CLC, LGALS3 and LGALS12, and LGALS8 and LGALS9 were evaluated for
both BM (blue, n=70) and AML (red/black, n=126) galectin gene expression.
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Figure 26: Pairwise scatter plots of Spearman's correlation indicates a change in
LGALS and NCF1/2 gene expression regulation in AML patients.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and the data log2 transformed prior to statistical analysis.
Correlations and regression line analysis between LGALS1 and NCF1/2, LGALS3 and
NCF1/2, and LGALS8 and NCF1/2 were evaluated for both BM (blue, n=70) and AML
(red/black, n=126) gene expressions.
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Figure 27: Survival curve analysis of TCGA AML patient data showed that LGALS
gene expression is related to patient outlook.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression when
comparing patient prognosis for all AML cohorts (n=160) for LGALS1 (A) and LGALS1
(B), LGALS4 (C), CLC (D) in all M0 subtype cohorts (n=15). Statistical significance was
determined using the log-rank (Mantel-Cox) test.
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Chapter 4

4

Discussion

The results obtained in this study indicate galectin specific effects on neutrophilic
differentiation of HL-60 promyeloid leukemia cells.

Additionally, HL-60 cells

demonstrated resistance to galectin-induced apoptosis. Furthermore, I showed that specific
galectin gene expression profiles can serve as new diagnostic and prognostic markers for
AML and specific FAB subtypes. Lastly, correlation analysis revealed changes in galectin
relationships between gene pairs.
I first showed that recombinant galectin-1 or -3 had no effect on neutrophilic differentiation
of HL-60 cells based on dose-dependent and daily supplementation treatments. However,
galectin-8 at 1000 ng/mL induced moderate levels of neutrophilic differentiation relative
to ATRA treated cells, with no effect observed with daily supplementation. Galectin-9
induced a similar response to galectin-8 with increased NCF1 expression, that was not
observed with daily supplementation. Next, I demonstrated that permeable allosteric
inhibitors specific to galectin-1 or -3 induced moderate levels of neutrophilic
differentiation of HL-60 cells relative to ATRA-induced differentiation. These findings
were confirmed by examining the segmentation of cell nuclei, genetically by expression of
associated biomarkers, and through global changes in O-GlcNAcylation, with ATRA
serving as a hallmark for these differentiation changes. Lastly, experiments related to the
third objective of this study revealed that galectin gene expression does not change in
leukemic cells relative to healthy cells, with more specific changes observed when
investigating different AML FAB subtypes. The M0-M2 FAB subtypes revealed no
changes in galectin gene expression, while the M4 and M5 subtypes demonstrated changes
in LGALS1 and LGALS3 expression, and the M3 subtype demonstrated significant changes
in galectin gene expression. Furthermore, correlation analysis revealed changes in the
relationship of galectin gene pairs between AML and bone marrow cohorts. Finally,
survival analysis revealed that above median expression of LGALS1 in AML cohorts can
serve as a marker for poor patient outlook, while above median expression of LGALS1,
LGALS4, and CLC can serve as markers for poor patient outlook in the M0 subtype.
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4.1 Interpretation
4.1.1

ATRA-induced differentiation provided insight into
understanding potential mechanisms behind neutrophilic
differentiation of HL-60 cells

ATRA has been used as a differentiation agent in research as well as a clinical treatment
of APL (Lohse et al., 2018).

There has also been increased interest in terminal

differentiation treatments for leukemias to decrease leukemic burden. Signal transduction
pathways related to terminal differentiation cause changes in gene expression that halt cell
mitosis and drive cells to become mature leukocytes, losing their proliferative ability
(Chaplinski et al., 1986; Mollinedo et al., 1998). ATRA-induced differentiation of HL-60
cells affects many signal transduction pathways and transcription factors including
ERK1/2, p38/MAPK, STAT3 and many others (Hickestein et al., 1989; Song et al., 2013).
In this study, I showed that ATRA-induced differentiation of HL-60 cells resulted in
increased segmentation of nuclei, upregulated NCF1 expression and decreased global OGlcNAcylation over 3 days.

Olins et al. (2000) reported that ATRA-induced

differentiation caused increased expression of lamin, cytoskeletal reorganization and
related nuclear lobulation related to neutrophilic differentiation over 4 days. Additionally,
Niggili et al. (2004) reported that the MAPK pathway is related in chemotactic peptide
induced actin reorganization and polarity development in HL-60 cells. Previous research
with ATRA revealed that RARα activation results in the formation of the RARα-RXR
complex. This complex activates and upregulates transcription factors PU.1 and C/EPBα/β
(Tasseff et al., 2017). Tasseff et al. (2017) also reported that ATRA activation results in
the activation of ERK1/2 and MAPK pathway, causing binding of CEBPα/β, and PU.1 to
promoter regions. This resulted in upregulation of neutrophil differentiation specific
markers including CD11b (integrin αM) and NCF1 in HL-60 cells. Furthermore, Hickstein
et al. (1989) reported that undifferentiated HL-60 cells express integrin αM, with retinoic
acid differentiated HL-60 cells expressing higher levels of integrin αM. ATRA-induced
differentiation of HL-60 cells also downregulates signal transducers and activator of
transcription 3 (SATA3) expression, a known signal transduction protein associated with
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the continuous proliferation of undifferentiated cells, and CD44, a surface glycoprotein
involved with cellular adhesion and migration (Liu et al., 2007; Song et al., 2013).
Prior research with HL-60 cells have shown that undifferentiated cells contain higher levels
of global O-GlcNAcylation (Sherazi et al., 2018). Cancerous cells have been reported to
have increased glycolysis for energy production, which allows for continuous proliferation
and increased O-GlcNAcylation through the hexosamine biosynthetic pathway (Asthana
et al., 2018). O-GlcNAcylation status in cancer cells is related to a variety of metabolismsensing signaling pathways including MAPK, mTOR, and AMPK due to the protein being
O-GlcNAcylated (Sanches-Garrido J & Shenoy AR, 2020). In mouse melanoma, increased
levels of O-GlcNAcylation promoted cancer progression, while a downregulation of
p38/MAPK and upregulation of ERK1/2 were observed (Moriwaki & Asahi, 2017).
Additionally, Wu et al. (2020) reported that O-GlcNAcylation of phosphorylated STAT3
altered downstream gene activation of genes associated with proliferation.
While ATRA- and DMSO-induced differentiation revealed changes in nuclear
morphology, NCF1 regulation, and global O-GlcNAcylation, they also revealed changes
in galectin gene expression. More specifically, LGALS3 and CLC were upregulated in
differentiated cells, LGALS1 and LGALS12 were downregulated in differentiated cells, and
LGALS8 and LGALS9 were constantly expressed (Abedin et al., 2003; Timoshenko et al.,
2016; Vinnai et al., 2017; Vakhrusnev et al., 2018). In this study, I demonstrated that
galectins have no significant effect on ATRA-induced differentiation of HL-60 cells. HL60 cells treated with 1 µM ATRA revealed strong stimulatory effects relative to galectininduced differentiation.

Therefore, an experiment was performed with 500 ng/mL

recombinant galectin 1, 3, or 8 to investigate whether galectins influenced the
differentiation of HL-60 cells with 5 nM ATRA. However, no significant changes were
observed in nuclear morphology, NCF1 expression or global O-GlcNAc. While 5 nM
ATRA induced half the response of 1 µM ATRA, galectins exhibited no effects due to
ATRA-induced strong stimulatory effects (Figure S1).
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4.1.2
4.1.2.1

Proto-type galectins -1, -7 and -10
Galectin-1 allosteric inhibition induces moderate levels of
cellular differentiation and demonstrates changes in gene
expression related to AML FAB subtype and prognosis

To date, galectin-1 has been investigated in the differentiation of many cell models
including eosinophil, macrophage, monocyte, trophoblast, keratinocyte, and hematopoietic
stem cells (Abedin et al., 2003; Vas et al., 2004; Sarafian et al., 2006; Novak et al., 2012,
Tang et al., 2018). Additionally, there are many instances where inhibition, knockdown,
or use of recombinant galectin-1 has been investigated with respect to its role in
differentiation and cancer progression. However, an understanding of the effects of
galectin-1 in AML and granulocytic differentiation is lacking.
More specifically, Vas et al. (2004) reported that recombinant galectin-1 can induce
differentiation of early hematopoietic stem cells.

Furthermore, galectin-1 induced

neutrophil migration during anti-inflammatory responses through the p38/MAPK pathway
(Auvynet et al., 2013). To date, there are multiple galectin-1 inhibitors available including
TDG, a broad functioning sugar inhibitor, and OTX008, a specific, permeable allosteric
inhibitor. OTX008 is also under investigation in clinical trials with respect to its potential
for cancer therapeutics through galectin-1 inhibition (Michael et al.,2016). In this study, I
observed that HL-60 cells treated with TDG or recombinant galectin-1 did not demonstrate
changes in neutrophilic differentiation, while OTX008 inhibition induced differentiation.
This may indicate that the non-CRD region of galectin-1 plays a role in the regulation of
promyeloid cells during neutrophilic differentiation of HL-60 cells.

Previous

investigations with OTX008 reported inhibition of the proliferation of HL-60 cells and the
downregulation of ERK1/2 (Astorgues-Xerri et al., 2014). Additionally, treatment of
HRAS-mutant cancers demonstrated that OTX008 inhibition blocked ERK1/2 MAPK
signaling through prevention of galectin-1 and HRAS intracellular binding (Michael et al.,
2016). In AML, galectin-1 is considered a pro-survival molecule through the assembly of
RAS complex intracellularly, which causes activation of the ERK1/2 MAPK pathway
(Ruvolo, 2019). Additionally, Paz et al. (2018) reported that OTX008 inhibition of
galectin-1 in acute lymphocytic leukemia (ALL) inhibited integrin-mediated adhesion and
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migration of ALL cells. Paz et al. (2018) also observed increased levels of galectin-1
surface expression. In addition, research using recombinant galectin-1 on stimulated
neutrophils demonstrated inhibited expression of integrin αM, a known receptor associated
with neutrophil function through ERK/p38/MAPK activation.

siRNA mediated

knockdown of galectin-1 resulted in enhanced neutrophil recruitment and emigration often
associated with integrin binding, suggesting that galectin-1 may inhibit integrin αM
responses (Cooper et al., 2008). Furthermore, Luo et al. (2016) demonstrated that galectin1 in chronic myeloid leukemia (CML) K562 cells served as a mediator for drug resistance
signaling through the MAPK pathway. Therefore, more investigation is needed to better
understand the signal transduction mechanisms behind the role of galectin-1 in regulating
neutrophil differentiation and function, with modulation of ERK1/2 MAPK signaling as a
potential mechanism behind maintaining an undifferentiated and cancerous status.
Galectin-1 in blood cancers has been viewed as a pro-survival molecule and poor
prognosis. Juszczynski et al. (2011) determined that galectin-1 gene expression was
upregulated in 100% of MLL-related ALL, while Paz et al. (2018) indicated an
upregulation in LGALS1 in non-MLL related ALL. In this study, I found that LGALS1
expression was constant when looking at all AML cohorts. However, LGALS1 expression
was elevated in the M4 and M5 FAB subtypes as was observed with neutrophil
differentiation markers (NCF1/2, CYBA/B) and LGALS3 (Figure S3). Ruvolo et al. (2020)
reported that shRNA mediated knockdown of LGALS1 in the M4 cell line OCI-AML3,
demonstrated prolonged survival and a decreased the rate of leukemic burden in
xenografted mice. This was also confirmed in this study where above median expression
of LGALS1 in all AML cohorts and the M0 subtype was indicative of poor prognosis.
Above median expression of LGALS1 also demonstrated a non-significant trend for poor
prognosis in all AML FAB subtypes investigated in this study, except for the M5 subtype
(Figures S6-S10). Knockdown of galectin-1 in multiple myeloma cells also results in
decreased tumor size, indicating that in blood related cancers that galectin-1 serves as a
poor prognostic marker (Storti et al., 2016). Finally, correlation analysis showed multiple
changes in the relationships between LGALS1 gene pairs including LGALS3, CLC, and
NCF1/2. Almkvist et al. (2002) indicated that galectin-1 is involved with the activation of
the NADPH-oxidase complex. However, the relationship between LGALS1 and NCF1/2
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in leukemia has yet to be investigated. Additionally, there has been no investigations into
the relationship between LGALS1 and LGALS3 or CLC. This indicates that LGALS1 has an
important role in the progression of AML, with further investigations needed to understand
the underlying mechanisms.

4.1.2.2

Galectin-10 gene expression indicated patient prognosis,
while galectin-7 and galectin-10 gene expression remained
constant in AML FAB subtypes

Previous research into galectin-7 expression has reported upregulation in keratinocyte
differentiation and constant gene expression during enterocytic differentiation (Sarafian et
al., 2006; Sherazi et al., 2018) Additionally, the gene expression of galectin-10 has only
been examined during neutrophilic differentiation of HL-60 cells (Abedin et al., 2003;
Vinnai et al., 2017). Galectin-7 and -10 are not as well-studied as the other galectins for
their involvement in AML. Currently, galectin-7 and galectin-10 have been identified in
AML (De Kouchkiveky & Abdul-Hay, 2016l Su, 2018). In this study, I showed that
LGALS7 and CLC exhibit constant expression.

I also observed that above median

expression of CLC was indicative of poor prognosis in the M0 subtype. To date, there are
limited single studies of galectin-7 in cancer that are related to its gene expression changes.
Galectin-7 has been reported to be upregulated in esophagus, breast, thyroid, pharynx and
larynx cancers. Furthermore, galectin-7 has been reported to be downregulated in skin,
cervix, and stomach cancers (Thijssen et al., 2015). In contrast, the expression patterns of
galectin-10 are unreported in other cancers. Galectin-10 has been investigated for its
involvement with eosinophils and its suppression function of Treg cells.

However,

galectin-10 suppression of T cells has yet to be investigated in leukemias. Therefore, more
investigations are needed to fully understand the roles of galectin-7 and -10 in AML.

4.1.3

Chimeric type galectin-3 allosteric inhibition induces
moderate levels of HL-60 cell differentiation

Galectin-3 is the sole chimeric-type galectin that is as well-studied as galectin-1. Galectin3 exhibits increased expression in DMSO treated HL-60 cells and elicits responses through
its CRD and N-terminal domains (Abedin et al.,2003; Vinnai et al., 2017; Sundqvist et al.,
2018).

Galectin-3 has been investigated in the differentiation of many cell models
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including adipocyte, CD34+ mononuclear cells, enterocyte, eosinophil, keratinocyte M1
macrophages, monocyte, oligodendritic cell, osteoblast, B cells, and trophoblast cells
(Tazhitdinova & Timoshenko, 2020). There have also been investigations into galectin-3
activities with mature neutrophils, expression patterns during neutrophilic differentiation,
and AML cancer progression. Currently, there is little understanding of the involvement
of galectin-3 in the differentiation of neutrophils.
In this study, I observed that recombinant galectin-3 or TDG demonstrated no effect on
neutrophilic differentiation of HL-60 cells, whereas induction was observed with the
permeable, specific allosteric inhibitor GB1107.

This may indicate that galectin-3

regulated promyeloid cell neutrophilic differentiation through the N-terminal domain,
rather than through CRD binding. Galectin-3 has been reported to be involved with primed
neutrophil responses rather than naïve and unprimed neutrophils. Nieminen et al. (2005)
reported that galectin-3 increased integrin expression in primed neutrophils, and elicited
no effect on naïve, unprimed neutrophils. Additionally, Sundqvist et al. (2018)
demonstrated that galectin-3 elicited ROS production in primed neutrophils that was
unseen in unprimed neutrophils. Sundqvist et al. (2018) also demonstrated that the cleaved
CRD portion of galectin-3 inhibited this response in primed neutrophils and that the Nterminal domain of the protein was required ROS production.
Furthermore, galectin-3 demonstrated properties that would enhance cellular proliferation
and survival rather than differentiation. Galectin-3 is known to be involved with cellular
division through interaction with NuMA (Magescas er al., 2017). Prior reports of galectin3 indicated that it is involved with the activation of the Wnt/β-catenin pathway. The
activation of the Wnt/β-catenin pathway is associated with poor prognosis and increased
proliferation in AML and other cell types (Hu et al., 2015; Ruvolo et al, 2018). In human
thyroid and orthotopic gastric cancer, galectin-3 inhibition by GB1107 resulted in
increased levels of phosphorylated p38 and AKT, decreased phosphorylation of ERK, and
decreased activation and expression of STAT3 and β-catenin (Kim et al., 2021; Lee et al.,
2021). Previous research with gastric cancer also revealed that activation of STAT3 by
Wnt required endogenous galectin-3 (Kim et al., 2021). Additionally, Kim et al. (2021)
also demonstrated that overexpression of galectin-3 activated STAT3 through direct
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binding by co-immunoprecipitation and regulated the DNA binding and transcriptional
activation of STAT3. GB1107 inhibition also exhibited inhibited activation of both Wnt
and STAT3 signaling pathways. Jeon et al. (2010) reported that galectin-3 demonstrated
cytokine-like regulatory actions through the JAK-STAT pathway in brain immune cells.
Bhattacharyya et al. (2014) also reported activity in Sp1 binding to Wnt promoter regions
that was prevented by galectin-3 inhibition. Furthermore, in MSCs, elevated levels of
galectin-3 were positively correlated with β-catenin, indicating a functional association
(Ruvolo et al., 2018). Therefore, the N-terminal domain of galectin-3 potentially regulates
promyeloid cell differentiation through Wnt/β-catenin and STAT3 pathways.
Currently, galectin-3 has been investigated for its relation to age, therapeutic enhanced
resistance, and involvement in the cancer microenvironment of leukemias. Ruvolo et al.
(2018) reported that galectin-3 protein expression was higher in AML MSC, Gao et al.
(2016) demonstrated elevated gene expression in non-APL AML, and El Leithy et al.
(2015) demonstrated no change in LGASL3 expression. However, in this study, I found
that LGASL3 expression was unchanged in all AML cohorts. This difference could be due
to the different sample subtype composition and leukemia burden. El Leithy et al. (2015)
reported 53 patients (15 M0/M1, 17 M2, 5 M3, and 16 M4), while Ruvolo et al. (2018)
reporting 106 MSC AML patients, and Gao et al. (2016) reported 298 non-APL AML
patients. Furthermore, Cheng et al. (2013) reported a downregulation in LGALS3
expression in the M1 subtype, and upregulation in the M4 and M5 FAB subtypes that was
also observed in this study.

Cheng et al. (2013) also indicated that older patients

demonstrated increased LGALS3 expression in bone marrow samples and were often
associated with M4 and M5 subtypes, with no other variables influencing galectin-3
expression. Cheng et al (2013) also demonstrated that patients with lower LGALS3
expression survived an additional 23.5 months. In this study, we observed that LGALS3
expression demonstrated no diagnostic or prognostic potential. However, patient age was
undetermined in this study and contained altered FAB subtype patient composition.
Additionally, in this study, LGALS3 gene pairs showed changes from negative to positive
correlations with granulocyte differentiation markers NCF1/2 and CYBA/B.

While

Sundqvist et al. (2018) showed that galectin-3 induces ROS production in neutrophils, this
relationship has yet to be investigated in AML.
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4.1.4
4.1.4.1

Tandem-repeat type galectins -4, -8, -9, and -12
Recombinant galectin-8 induces moderate levels of cellular
differentiation, while galectin-4 gene expression indicates
patient prognosis with constant gene expression in AML
FAB subtypes

During HL-60 cell differentiation, galectin-8 demonstrates constant expression patterns
(Abedin et al., 2003; Timoshenko et al., 2016; Vinnai et al., 2017). Galectin-8 gene
expression has been reported to be downregulated in plasma cell differentiation and
enterocyte differentiation, with constant gene expression observed in eosinophilic,
monocytic, and trophoblastic differentiation (Abedin et al., 2003; Arikawa et al., 2012;
Ikegame et al., 2016; Sherazi et al., 2018). In this study, I observed that recombinant
galectin-8 induced neutrophilic differentiation of HL-60 cells. To date, little is known with
respect to the regulatory functions of galectin-8 in neutrophils and their differentiation.
However, in Jurkat T cells, the binding of galectin-8 to extracellular integrins results in
strong stimulation of ERK1/2 (Cárcamo et al., 2006). Integrins are important for neutrophil
function through ERK and p38/MPAK activation, which is involved in cellular adhesion
and spreading, chemotaxis, and production of ROS. Nishi et al. (2003) reported that bound
galectin-8 to integrin αM required the C-terminal CRD region for activation. Reports have
also indicated that integrin αM expression is upregulated in differentiated cells, with a basal
level observed in undifferentiated cells (Hickstein et al., 1989). However, galectin-8
induced differentiation was not observed with daily supplementation, indicating that
activation through integrin αM is time sensitive.

Therefore, galectin-8 induced

differentiation through the proposed binding of the C-terminal CRD to integrin αM,
activating p38/MAPK, with further investigations required.
However, recombinant galectin-8 demonstrated sustained O-GlcNAcylation status. To
date, the involvement of the ERK or p38/MAPK pathways with O-GlcNAcylation in HL60 cells is undetermined. In mouse melanoma, increased levels of O-GlcNAc promote
cancer progression and downregulation in p38/MAPK, while also upregulating ERK1/2
(Moriwaki & Asahi, 2017). Additionally, Cárcamo et al. (2006) indicated that extracellular
binding of galectin-8 to integrins results in the activation of ERK1/2. Therefore, this

89

suggests that galectin-8 binding to integrin αM not only activates p38/MPAK but also
activates ERK1/2, maintaining O-GlcNAcylation status in HL-60 cells.
Galectin-8 is poorly studied with respect to its functions associated with leukemia.
Investigations into other cancers have demonstrated upregulation in LGALS8 (Nagi et al.,
2002; Genetilini et al., 2017; Trebo et al., 2020). In this study, I found that LGALS8
expression was unchanged in AML cohorts; and downregulated in the M3 subtype. El
Leithy et al. (2015) reported that LGALS8 expression was constant. El Leithy et al. (2015)
also indicated that galectin-8 was not a marker for prognosis. I also observed that LGALS8
expression was not indicative of prognosis in all AML cohort and FAB subtypes (Figures
S4-S10). Additionally, LGALS8 gene pair showed changes in relationships from negative
to positive with NCF1/2. Nishi et al. (2003) indicated that galectin-8 induced ROS
production in neutrophils. However, the relationship between LGALS8 and NCF1/2 in
AML has yet to be investigated. Additionally, LGALS8 also demonstrated a positive
correlation with LGALS9 expression in cancerous cells. To date, little is known with
respect to how LGALS8 expression is associated with other galectin gene expression in
AML, indicating that further investigations are needed.
Studies of galectin-4 have reported downregulation in colon, prostate, and skin cancer, and
an upregulation in pancreas, liver, ovary, and bladder cancer (Thijssen et al., 2015). El
Leithy et al. (2015) reported that LGALS4 exhibited constant gene expression. El Leithy
et al. (2015) also indicated that LGALS4 is upregulated in younger patients and is indicative
of a better patient outlook. In this study, we found that LGALS4 expression was constant
in all AML cohorts, with upregulation observed in the M3 subtype. I also observed that
above median expression of LGALS4 was indicative of poor prognosis. There is little
understanding on how galectin-4 is involved with AML, indicating additional
investigations are needed.
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4.1.4.2

Recombinant galectin-9 induces NCF1 expression in
relation to cellular differentiation, while galectin-9 and
galectin-12 gene expression in the AML M3 subtype serves
as a diagnostic marker

Galectin-9 is another galectin expressed in HL-60 cells that demonstrates constant
expression during differentiation (Abedin et al., 2003; Timoshenko et al., 2016; Vinnai et
al., 2017). To date, the interaction of galectin-9 and Tim-3 has been of primary focus in
neutrophil activation and recruitment (Vega-Carrascal et al., 2011; Hirao et al., 2015;
Robinson et al., 2019). Prior research into galectin-9 reported expression changes during
eosinophil, macrophage, monocyte, osteoblast, trophoblast, and CD4+ T cell
differentiation (Tazhitdinova & Timoshenko, 2020). However, overexpression of galectin9 in macrophages increased activity and expression levels of STAT3.

In healthy

individuals, STAT3 has been reported to be involved in the upregulation of NADPH
oxidase components, including NCF1, and binding of C/EBPβ during myelopoiesis (Lu et
al., 2017).

However, in HL-60 cells, STAT3 expression is associated with an

undifferentiated state, allowing for continuous proliferation (Song et al., 2013). Tanikawa
et al. (2010) indicated that galectin-9 induced osteoblast differentiation through binding of
CD44. Liu et al. (2007) determined that ATRA-induced differentiation of HL-60 cells
downregulated CD44. Additionally, Liu et al. (2007) indicated that CD44 activation in
polymorphonuclear neutrophils activated ERK1/2 and p38/MAPK affecting actin
polymerization and enhanced neutrophil function. In this study, I found that recombinant
galectin-9 increased NCF1 expression, exhibited a non-significant increasing trend in the
percentage of segmented nuclei and elicited no change in O-GlcNAcylation. Furthermore,
daily supplemented galectin-9 had no effect. Downregulation of CD44 could be a possible
explanation for why galectin-9 was unable to induce differentiation. However, more
investigations are required. Therefore, galectin-9 elicited a similar response to galectin-8
through CD44 activation, activating both p38/MAPK to induce nuclear reorganization and
upregulation of NCF1 and activating ERK1/2 to maintain O-GlcNAcylation levels.
Current investigations of galectin-9 in AML revolve around immune surveillance escape
due to Tim-3 regulation of T cells and promoted myeloid-derived suppressor cells.
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Gonçalves Silva et al. (2016) reported that Tim-3 is highly expressed in AML and is
required for the secretion of galectin-9. Furthermore, Wdowiak et al. (2018) showed that
galectin-9 levels were increased in the serum of chronic lymphocytic leukemia (CLL)
patients that might have a role in the cancer progression. Taghiloo et al. (2017) also
reported that galectin-9 expression is upregulated in CLL relative to peripheral blood
mononuclear cells. El Leithy et al. (2015) investigated the expression of LGALS9 in AML
with constant gene expression being observe. El Leithy et al. (2015) also demonstrated
that LGALS9 expression was not indicative of patient prognosis. In this study, I found that
LGALS9 expression demonstrated upregulation in all AML cohorts and downregulation in
the M3 subtype. Additionally, LGALS9 in this study demonstrated no indications towards
patient prognosis. However, the role galectin-9 has in leukemias is not fully understood.
Kuroda et al. (2010) reported that galectin-9 induced apoptosis of chronic myeloid
leukemia (CML) cells, while also re-sensitizing various treatments in resistant CML.
In this study, I found that LGALS12/LGALS9 expression is a diagnostic marker for the M3
subtype. Currently, little is known with respect to the involvement of galectin-12 in AML.
El Leithy et al. (2015) reported a downregulation in LGALS12, which served as an indicator
of poor prognosis. Additionally, Zheng et al. (2019) stated LGALS12 expression is
upregulated in the M3 subtype. However, in this study, LGALS12 expression in all AML
cohorts remained constant, with an upregulation observed in the M3 subtype. El Leithy et
al. (2015) demonstrated a different AML patient subtype composition relative to this study,
indicating that a larger sample size or investigation into individualize subtypes is required.
Furthermore, Helbawi et al. (2021) reported that methylation plays a role in the survival of
patients when looking at LGALS12 expression, with methylated LGALS12 gene being
indicative of poorer prognosis. However, in this study, LGALS12 was not an indicator of
patient outlook, with methylation status being uninvestigated.

4.1.5

HL-60 cells exhibit resistance to galectin-induced apoptosis

In this study, I also examined the degree of apoptosis of HL-60 cells. HL-60 cells were
treated with various concentrations of brefeldin-A (BFA), a known inducer of apoptosis.
Previous research with BFA has reported that BFA induces endoplasmic reticulum (ER)
stress through inhibition of protein transport between ER and Golgi apparatus (Shao et al.,
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1996). Additionally, Choi et al. (2010) and Namba et al. (2013) report that ER induced
stress from BFA caused induction and activation of both CHOP and BAX, resulting in
apoptotic cell death. Additionally, Wei et al. (2008) revealed that 24 hours treatments of
BFA caused nuclear condensation and annexin V binding to phosphatidylserine of cell
membranes. In this study, I demonstrated that BFA exhibited nuclear condensation, and
upregulation of both CHOP and BAX in the HL-60 cell model.
In this study, I also examined the effect of ATRA on apoptosis of HL-60 cells. I revealed
that 1 µM ATRA did not induce apoptosis of HL-60 cells over 3 days. Veselská et al.
(2003) conducted a study with 1 µM ATRA and revealed that apoptotic cell death was
achieved over 6 days. Furthermore, Ozeki et al. (2008) reported that 2 µM ATRA resulted
in differentiation and apoptosis of HL-60 cells after 4 days. Based on the previous studies,
HL-60 cells exhibited resistance to apoptosis from 1 µM ATRA treatments over 3 days.
Galectins -1, -3, -4, -7, -8, -9, -10, and -12 have all been reported to induce apoptosis in
either immune or cancer cells (Timoshenko, 2015). However, the effects of galectins on
HL-60 cell apoptosis have yet to be examined. In this study, I showed that recombinant
galectins -1, -3, and -9 did not cause apoptosis of HL-60 cells. However, HL-60 cell
treatments with recombinant galectin-8 revealed increased DNA condensation, with
unchanged gene expression of CHOP and BAX. To date, treatments with only recombinant
galectin-1 have been performed to investigate the effects of galectins on apoptosis. Vas et
al. (2005) performed a study with 10 g/mL recombinant galectin-1 on the differentiation
and apoptosis of early hematopoietic stem cells and demonstrated apoptosis after 60 min
and complete cell death after 14 days. Additionally, Rabinovich et al. (1999) revealed that
4 µg/mL of recombinant galectin-1 induced high levels of apoptosis over 18 hours. This
indicates HL-60 cells are resistant to recombinant galectin-induced apoptosis under the
parameters set in this study.

4.2 Conclusions and applications
In conclusion, galectins have a role in the regulation of neutrophilic differentiation of HL60 cells and in AML.

Galectins have similar structures and function, indicating

evolutionary redundancies.

In this study, I observed that galectins have their own
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expression profiles in AML and had different effects on neutrophilic differentiation
through different proposed signaling pathways.

Furthermore, ATRA-induced

differentiation of HL-60 cells demonstrated a strong stimulated response, which masked
the effects of galectins and galectin inhibitors on neutrophilic differentiation. Finally, HL60 cells exhibited resistance to galectins and ATRA induced apoptosis.
Galectin-1 exhibited increased gene expression in the M4 and M5 subtypes of AML. While
LGALS1 expression has yet to be investigated by others among AML FAB subtypes,
LGALS1 expression was reported to increase in ALL (Juszczynski et al., 2011; Paz et al.,
2018). Additionally, above median gene expression of LGALS1 was indicative of poor
prognosis in all AML cohorts and the M0 subtype. Upregulation of LGALS1 was also
indicative of increased leukemia burden and poor prognosis in the M4 subtype as reported
by Ruvolo et al. (2020).

Furthermore, OTX008 inhibition of galectin-1 resulted in

neutrophilic differentiation of HL-60 cells. Therefore, it is suggested that intracellular
binding of non-CRD regions of galectin-1 to HRAS allows for p38/MAPK pathway
activation, potentially maintaining the undifferentiated state of HL-60 cells (Figure 28).
Inhibitory therapeutics, specifically OTX008, should be further investigated for AML.
Galectin-3 demonstrated similar trends as to galectin-1, except for upregulation being
reported in differentiated HL-60 cells (Abedin et al., 2003; Vinnai et al., 2017). Various
reports on LGALS3 expression in AML indicated upregulation (Ruvolo et al., 2018; Gao
et al., 2016), with upregulation of LGALS3 expression also reported in more mature
subtypes (Cheng et al., 2013). Cheng et al. (2013) also indicated that LGALS3 expression
increased with age, with older patients with AML being diagnosed with the M4 and M5
subtypes. Cheng et al. (2013) demonstrated that upregulation of LGALS3 was indicative
of poor prognosis, indicating that LGALS3 does play a role in the M4 and M5 subtypes of
AML. In undifferentiated HL-60 cells, the N-terminal domain of intracellular galectin-3
plays a potential role in the maintenance of an undifferentiated status by Wnt/β-catenin and
STAT3 pathways (Figure 28). Furthermore, several reports have indicated that galectin3 does not elicit any responses in unprimed neutrophils, indicating a complex system
(Nieminen et al., 2005). Therefore, inhibitory therapeutics of galectin-3 should be further
investigated for AML and proper immune cell function.
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Figure 28: Hypothetical galectin mediated regulation of granulocytic differentiation
of HL-60 cells.
OTX008 allosteric inhibition of galectin-1 intracellularly inhibits binding to HRAS,
preventing complex formation and no activation of ERK1/2 MAPK, resulting in induced
neutrophilic differentiation. Galectin-8 C-terminal CRD binding of integrin αM activates
signal transduction for activation of both ERK1/2 and p38/MAPK. ERK1/2 activation
maintains O-GlcNAcylation status while p38/MAPK activates the expression of genes
associated with nuclear reorganization and NCF1 expression. Galectin-9 binding to CD44
induces mechanisms similarly to galectin-8. GB1107 allosteric inhibition of galectin-3
intracellularly inhibits activation of both STAT3 and Wnt/β-catenin, allowing for
differentiation to occur.
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Galectin-8 is one of the galectins in HL-60 cells and AML that demonstrated consistent
expression patterns during neutrophilic differentiation and AML (Abedin et al., 2003; El
Leithy et al., 2015; Vinnai et al., 2017). Little is known with respect to the role of galectin8 in AML. However, recombinant galectin-8 demonstrated potential for a new differential
therapeutic for AML. In the HL-60 cell model, galectin-8 induced moderate levels of
differentiation. Several other reports indicated that the C-terminal CRD of galectin-8 binds
to integrin αM in neutrophils, activating both ERK1/2 and p38/MAPK pathways that is
time-dependent (Figure 28).

This signal transduction pathway suggests a potential

mechanism in which galetin-8 regulates neutrophilic differentiation of HL-60 cells.
Galectin-9 has been widely investigated for its interaction with Tim-3 in cancer progression
through evasion of T cell surveillance. In leukemias, Tim-3 has increased expression that
allows for increased secretion of galectin-9, detectable in patient serum (Wdowiak et al.,
2018). However, due to the interaction of galectin-9 with Tim-3, it has gained more interest
in lymphocytic leukemias. To date, there is one other study looking at LGALS9 expression
in AML that reported constant gene expression and no prognostic potential (El Leithy et
al., 2015). However, in this study we found downregulation of LGALS9 in the M3 subtype.
LGALS9 expression has also been reported to be constant during induced differentiation of
HL-60 cells (Vinnai et al., 2017). I also found that recombinant galectin-9 demonstrated
increased NCF1 expression and potential increase in segmented nuclei that could be due to
CD44 binding, activating both ERK1/2 and p38/MAPK similarly to galectin-8 (Figure 28).
Galectins 4, 7, 10, and 12 are poorly studied with respect to their expression patterns and
roles in AML cancer progression and blood cell maturation. Galectin 4 and 7 have been
demonstrated to exhibit changes in expression in other cancer models, with single reports
only being investigated and no reports of galectin-10 (Thijssen et al., 2015). However,
LGALS4 and LGALS10 served as poor prognostic indicators in the M0 subtype that require
further investigations. Additionally, LGALS12 is upregulated in the M3 subtype (Zheng et
al., 2019). A specific ratio of LGALS12/LGALS9 served as a new diagnostic marker of M3
subtype identified in this study. Additionally, the methylation status of the LGALS12 gene
demonstrated potential as a prognostic marker (Helbawi et al., 2021).
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4.3 Study limitations and future directions
The results of this study showed that galectins do have a role in the neutrophilic
differentiation of HL-60 cells.

Additionally, galectins serve as new diagnostic and

prognostic markers in AML. However, there are a few limitations with this study.
In the HL-60 cell model, a larger sample size is required for some treatments. When
examining the effects of galectins on various aspects of neutrophilic differentiation, some
variations were observed within treatments. A way to overcome these variations would be
to increase sample size in order to get a more representative picture. Additionally, it is
common practice in medicine to have independent experts to examine fluorescent images
to eliminate bias. In this study, only one individual examined the percentage of segmented
nuclei. Furthermore, neutrophil functions were not examined in this study. As such,
increased NCF1 expression indirectly indicate NADPH oxidase activity. Additional tests
to assess neutrophilic function would help strengthen the results found this study.
HL-60 cells have been shown to produce ROS when differentiated into neutrophils (Vinnai
et al., 2017). However, to produce ROS, activation and phosphorylation by protein kinase
C is required to assemble the NADPH oxidase complex. In the HL-60 cell model, ROS
can be activated using chemical stimulation, including phorbol 12-myristate 13-acetate, or
bacterial cell wall components including formyl-methionyl-leucyl-phenylalanine (Dakik et
al., 2021). Once activated, the NADPH oxidase complex will create superoxide ions, the
precursor required for hydrogen peroxide production. Hydrogen peroxide production can
then be measured by scopoletin/peroxidase fluorescence assay (Bedard & Krause 2007;
Belambri et al., 2018). Additionally, flow cytometry of surface markers including an
upregulation in CD11b and downregulation in CD44 and CD15 would be another method
to assess neutrophilic differentiation.

RT-qPCR of other genetic markers including

downregulation in C-MYC and upregulation of lamin are other indicators to assess
neutrophilic differentiation.
To date, there are no known specific inhibitors of galectin 8, 9, 10, or 12. Additionally,
OTX008 and GB1107 may also have off targeting effects. Therefore, shRNA mediated
silencing would be another method to determine the direct effects of inhibition of galectins
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on HL-60 cell differentiation.

shRNA mediated silencing allows for the effects of

transfection to resolve before assessing neutrophilic differentiation by being a more stable
and less transient method. Additionally, recombinant galectins 10 and 12 were not
available for purchase and were not investigated in this study. Therefore, transfection of
E. coli cells with a plasmid expressing human recombinant galectn-10 and -12 can be
performed to obtain and test these recombinant galectins on differentiation of HL-60 cells.
In the HL-60 cell model, the mechanisms driving galectin regulated differentiation remains
unknown. There are several signal transduction pathways and transcription factors that
galectins interact with during various cellular processes. A method to assess these changes
in the expression of various transcription factors would be to perform the RT2 Profiler PCR
Array (Garcia-Peterson et al., 2020). Additionally, investigations into the expression of
ERK1/2, p38, MAPK, STAT3, HRAS, Wnt, β-catenin, and CD44 at a genetic and protein
level, and inhibition of these proteins, would also be beneficial to determine if these are a
part of the underlying mechanisms. Additionally, co-immunoprecipitation or fluorescent
co-localization imaging are two methods with which to assess the interaction of galectins
with the various proteins exogenously or endogenously.
To further assess the resistance of HL-60 cells to galectin-induced apoptosis,
concentrations above 1 µg/mL should be tested. Additional tests are also required and can
include annexin V staining and flow cytometry. Additionally, RT-qPCR and western blot
analysis for other markers including BCL2 and caspases should be performed.
When examining the AML TCGA data used in this study, there are some differences in the
results observed when compared to the literature. This could be due to several factors
including patient subtype sample composition, leukemic burden, age, various genetic
abnormalities, and sample size. Therefore, the same analysis performed in this study
should be conducted on a different set of AML samples. Furthermore, investigations at the
genetic level are half the picture. Assessment of galectins at the protein level, and their
methylation status, would further enhance our understanding of their involvement in AML.
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Appendix A: Supplementary Material
Table S1: Gene names, PCR primer sequences and amplicon sizes, cycling conditions,
efficiencies, and references.
Sequence 5’-3’

Gene name

Size

2 step cycling

(bp)

PMID
reference

mRNA RefSeq
NCF1

F GTCAGATGAAAGCAAAGCGA

NM_000265.7

R CATAGTTGGGCTCAGGGTCT

ACTB
NM_001101.5

F TCAGCAAGCAGGAGTATGACGAG

93

F CAGACTGATCCAACTGCAG

NM_004083.6

R GACTGGAATCTGGAGAGT

23147401

62°C (25 s)
265

95°C (5 s)

30504378

60°C (25 s)

R ACATTGTGAACTTTGGGGGATG

CHOP*

95°C (5 s)

280

95°C (5 s)

Designed

62°C (25 s)

NM_001195057.1
NM_001195056.1
NM_001195055.1
NM_001195054.1
NM_001195053.1
BAX**
NM_001291429.2

F TGGCAGCTGACATGTTTTCTGAC

195

R TCACCCAACCACCCTGGTCTT

95°C (5 s)

30069445

62°C (25 s)

NM_004324.4

Note:

*CHOP

transcript

variant

1

(NM_001195053.1),

transcript

variant

2

(NM_001195054.1), transcript variant 3 (NM_001195055.1), transcript variant 4
(NM_001195056.1), transcript variant 5 (NM_004083.6), and transcript variant 6
(NM_001195057.1) are recognized by this primer pair. **BAX transcript variant gamma
(NM_001291429.2) and transcript variant beta (NM_004324.4) are recognized by this
primer pair.
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Figure S1: Combination treatments with recombinant galectins and 50 nM ATRA
had no effect on granulocytic differentiation of HL-60 cells.
HL-60 cells were treated with combinations of 500 ng/mL of recombinant galectin-1, -3 or
-8 or treatments with 500 ng/mL galectin-1, -3 or -8 and 50 nM ATRA were conducted
over 72 hr. See Chapter 2 Materials and Methods for detailed explanation of techniques.
(A) Nuclear morphology of cells; (B) cell differentiation index; (C) cell apoptotic index;
NCF1 gene expression of recombinant galectins + ATRA treated cells (D) and galectin
combination treatments (E). Recombinant galectins + ATRA data represented as n=1.
Galectin combination data are presented as means ± SD, n=3. Significant differences were
determined using One-way ANOVA followed by Tukey’s HSD test with a p<0.05.
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Figure S2: O-GlcNAc related enzymes OGA, OGT, and GFAT1 exhibits constant gene
expression patterns in TCGA AML subtypes M0-M5.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and log2 transformed in Microsoft excel prior to
statistical analysis. The subtypes investigated include M0 (n=12), M1 (n=36), M2 (n=29),
M3 (n=12), M4 (n=22), and M5 (n=14) and compared to BM control (n=70). O-GlcNAc
related enzymes gene expression profiles of OGA, OGT, and GFAT1 were examined as
well as related ratios of OGA/OGT, OGA/GFAT1, and OGT/GFAT1. Data are represented
as violin plots. Statistical significance was determined using the nonparametric KruskalWallis test followed by Dunn’s multiple comparisons and are represented as different
letters with a p<0.05.
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Figure S3: Granulocyte differentiation markers and stemness markers demonstrates
changes in expression profiles in TCGA AML subtypes M0-M5.
GTEx bone marrow (BM) and TCGA AML RNA-Seq data were retrieved from recount2
and RUVg normalized in R studio and log2 transformed in Microsoft excel prior to
statistical analysis. The subtypes investigated include M0 (n=12), M1 (n=36), M2 (n=29),
M3 (n=12), M4 (n=22), and M5 (n=14) and compared to BM control (n=70). Granulocyte
differentiation markers NCF1, NCF2, CYBB, CYBA and MPO were investigated as well as
stemness markers OCT4, NANOG, FOX2, C-MYC, KLF4, and CD34. Data are represented
as violin plots. Statistical significance was determined using the nonparametric KruskalWallis test followed by Dunn’s multiple comparisons and are represented as different
letters with a p<0.05.
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Figure S4: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as well as OGlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML cohorts
(n=160). Statistical significance was determined using the log-rank (Mantel-Cox) test.
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Figure S5: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M0.
RSEM AML patient data was retrieved from cBioPortal and put to the log2 transformed. R
Studio was used to access patient survival data from cBioPortal. Median gene expression
was used to determine patients with above/equal (red) or below (black) expression.
Galectin genes including LGASL3, LGALS8, LGALS9, and LGALS12 as well as O-GlcNAc
related enzymes OGA, OGT, and GFAT1 were investigated in all AML M0 FAB subtype
(n=15). Statistical significance was determined using the log-rank (Mantel-Cox) test.
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Figure S6: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M1.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGALS1, LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as
well as O-GlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML
M1 FAB subtype (n=36). Statistical significance was determined using the log-rank
(Mantel-Cox) test.
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Figure S7: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M2.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGALS1, LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as
well as O-GlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML
M2 FAB subtype (n=36). Statistical significance was determined using the log-rank
(Mantel-Cox) test.
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Figure S8: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M3.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGALS1, LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as
well as O-GlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML
M3 FAB subtype (n=16). Statistical significance was determined using the log-rank
(Mantel-Cox) test.
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Figure S9: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M4.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGALS1, LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as
well as O-GlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML
M4 FAB subtype (n=34). Statistical significance was determined using the log-rank
(Mantel-Cox) test.
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Figure S10: Survival curve analysis of TCGA AML patient data of galectin and OGlcNAc genes expression is not associated with patient prognosis in FAB subtype M5.
RSEM AML patient data was retrieved from cBioPortal and log2 transformed. R Studio
was used to access patient survival data from cBioPortal. Median gene expression was
used to determine patients with above/equal (red) or below (black) expression. Galectin
genes including LGALS1, LGASL3, LGALS4, LGALS8, LGALS9, CLC, and LGALS12 as
well as O-GlcNAc related enzymes OGA, OGT, and GFAT1 were investigated in all AML
M5 FAB subtype (n=18). Statistical significance was determined using the log-rank
(Mantel-Cox) test
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